image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
fb22851cfd72b0c2cf5119cd07624f8199425b0e25784a9665b9dbf7595eaddf.png | simple | <table><tr><td>Comparison (5-Aza)</td><td>Methods</td><td>Cuffdiff</td><td>SAMSeq</td><td>baySeq</td><td>DESeq</td><td>Noiseq</td></tr><tr><td>5 μM vs 0 μM</td><td>T-test</td><td>25.8%</td><td>22.5%</td><td>24.5%</td><td>25.8%</td><td>29.7%</td></tr><tr><td></td><td>SAM</td><td>39.9%</td><td>39.9%</td><td>42.... | <table><tr><td>Comparison (5-Aza)</td><td>Methods</td><td>Cuffdiff</td></tr><tr><td>5 μM vs 0 μM</td><td>T-test</td><td>25.8%</td></tr><tr><td></td><td>SAM</td><td>39.9%</td></tr><tr><td></td><td>Ebayes</td><td>39.5%</td></tr><tr><td>10 μM vs 5 μM</td><td>T-test</td><td>0.5%</td></tr><tr><td></td><td>SAM</td><td>31.1%<... | <table><tr><td>SAMSeq</td><td>baySeq</td><td>DESeq</td><td>Noiseq</td></tr><tr><td>22.5%</td><td>24.5%</td><td>25.8%</td><td>29.7%</td></tr><tr><td>39.9%</td><td>42.7%</td><td>44.5%</td><td>33.5%</td></tr><tr><td>39.5%</td><td>42.2%</td><td>44.0%</td><td>33.3%</td></tr><tr><td>0.5%</td><td>0.6%</td><td>0.6%</td><td>0.0... |
6250b1f85974b989a6b9fac0b30e921f047441caa57399245c12ca92083030b4.png | simple | <table><tr><td></td><td><i>Local density</i></td><td><i>Coeff. variation nearest distances</i></td><td><i>Area</i></td></tr><tr><td><i>Local density</i></td><td>1.00</td><td>---</td><td>---</td></tr><tr><td><i>Coeff. Variation nearest distances</i></td><td>0.22*</td><td>1.00</td><td>---</td></tr><tr><td><i>Area</i></td... | <table><tr><td></td><td>Local density</td><td>Coeff. variation nearest distances</td><td>Area</td></tr><tr><td>Local density</td><td>1.00</td><td>---</td><td>---</td></tr></table> | <table><tr><td></td><td>Local density</td><td>Coeff. variation nearest distances</td><td>Area</td></tr><tr><td>Coeff. Variation nearest distances</td><td>0.22*</td><td>1.00</td><td>---</td></tr><tr><td>Area</td><td>-0.10</td><td>0.11</td><td>1.00</td></tr></table> |
d537e6bfb5728ac33a68d702cc71cd0bdcc8be5c13baf1a0d4ef1ff21d40f079.png | simple | <table><tr><td>Variable</td><td>Factor</td><td><i>P</i> value</td><td>HR</td><td>95.0% CI</td></tr><tr><td>Age</td><td>Continuous</td><td>0.367</td><td>1.02</td><td>0.98–1.05</td></tr><tr><td>Sex</td><td>Male</td><td>0.001</td><td>0.36</td><td>0.20–0.66</td></tr><tr><td>ECOG-PS</td><td>>1</td><td>0.034</... | <table><tr><td>Variable</td><td>Factor</td><td>P value</td></tr><tr><td>Age</td><td>Continuous</td><td>0.367</td></tr><tr><td>Sex</td><td>Male</td><td>0.001</td></tr><tr><td>ECOG-PS</td><td>>1</td><td>0.034</td></tr><tr><td>Comorbidities (CVD or DM)</td><td>Positive</td><td>0.084</td></tr><tr><td>Metastatic disease</td... | <table><tr><td>HR</td><td>95.0% CI</td></tr><tr><td>1.02</td><td>0.98–1.05</td></tr><tr><td>0.36</td><td>0.20–0.66</td></tr><tr><td>2.13</td><td>1.06–3.39</td></tr><tr><td>0.53</td><td>0.25–1.07</td></tr><tr><td>9.34</td><td>5.12–17.1</td></tr><tr><td>3.03</td><td>1.41–5.51</td></tr></table> |
2d98da39147020b154e4f7f8ed9454d29e5cfccec634723eef6725e75f2ba4bb.png | simple | <table><tr><td>miRNA</td><td>Target</td><td>Effector cell</td><td>Affected chemokine</td><td>Role in atherosclerosis</td><td>References</td></tr><tr><td>miR-181b</td><td>Importin-α3</td><td>ECs</td><td>CXCL1</td><td>Protective</td><td>[58]</td></tr><tr><td>miR-103</td><td>KLF4</td><td>ECs</td><td>CXCL1CCL2</td><td... | <table><tr><td>miRNA</td><td>Target</td><td>Effector cell</td><td>Affected chemokine</td><td>Role in atherosclerosis</td><td>References</td></tr><tr><td>miR-181b</td><td>Importin-α3</td><td>ECs</td><td>CXCL1</td><td>Protective</td><td>[58]</td></tr></table> | <table><tr><td>miRNA</td><td>Target</td><td>Effector cell</td><td>Affected chemokine</td><td>Role in atherosclerosis</td><td>References</td></tr><tr><td>miR-103</td><td>KLF4</td><td>ECs</td><td>CXCL1CCL2</td><td>Damaging</td><td>Unpublished</td></tr><tr><td>miR-126-3p</td><td>RGS16</td><td>ECs</td><td>CXCL12</td><td>Pr... |
c063090c45c98a7e74b27088f907ad1dbb0f9004e399a5961ef0d74f20bc1b5d.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">STIB900-M vs. STIB900</td><td colspan="3">STIB900-P vs. STIB900</td></tr><tr><td>Overall</td><td>CDS</td><td>NS</td><td>Overall</td><td>CDS</td><td>NS</td></tr><tr><td>Chr1</td><td>0</td><td>0</td><td>0</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Chr2</td><td>0</td><td... | <table><tr><td rowspan="2"></td><td colspan="3">STIB900-M vs. STIB900</td><td colspan="3">STIB900-P vs. STIB900</td></tr><tr><td>Overall</td><td>CDS</td><td>NS</td><td>Overall</td><td>CDS</td><td>NS</td></tr><tr><td>Chr1</td><td>0</td><td>0</td><td>0</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Chr2</td><td>0</td><td... | <table><tr><td>Chr5</td><td>2</td><td>0</td><td>0</td><td>1</td><td>Tb927.5.286b</td><td>G430R</td></tr><tr><td>Chr6</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Chr7</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Chr8</td><td>1</td><td>0</td><td>0</td><td>0... |
55f6c1b2e6563ffed7cddf95063e24944177a66ac6cfadb0bfc0d26ae5182229.png | complex | <table><tr><td></td><td colspan="6">Groups</td></tr><tr><td></td><td colspan="3">NH</td><td colspan="3">CI</td></tr><tr><td></td><td>Long, complex sentences</td><td>Highly meaningful sentences</td><td>Nonsense sentences</td><td>Long, complex sentences</td><td>Highly meaningful sentences</td><td>Nonsense sentences</td><... | <table><tr><td></td><td>Groups</td></tr><tr><td></td><td>NH</td></tr><tr><td></td><td>Long, complex sentences</td></tr><tr><td>Verbal Working Memory</td><td></td></tr><tr><td>LSpan (total letters correctly recalled)</td><td>.10</td></tr><tr><td>Rspan (total letters correctly recalled)</td><td>‐.01</td></tr><tr><td>Moda... | <table><tr><td colspan="5">Groups</td></tr><tr><td colspan="2">NH</td><td colspan="3">CI</td></tr><tr><td>Highly meaningful sentences</td><td>Nonsense sentences</td><td>Long, complex sentences</td><td>Highly meaningful sentences</td><td>Nonsense sentences</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><... |
79b13f563212c54a3431e49491e8f3e7e71995cc10bc59814848272eae82d655.png | simple | <table><tr><td>Parameters</td><td>No of patients with ≥ G2 RP (%)</td><td>No of patients with G0-1 RP (%)</td><td><i>p</i> value</td></tr><tr><td>Age</td><td></td><td></td><td>0.074</td></tr><tr><td> < 75 years old</td><td>1 (11)</td><td>25 (45)</td><td></td></tr><tr><td> ≥ 75</td><td>8 (89)</td><td>31 (... | <table><tr><td>Parameters</td><td>No of patients with ≥ G2 RP (%)</td></tr><tr><td>Age</td><td></td></tr><tr><td>< 75 years old</td><td>1 (11)</td></tr><tr><td>≥ 75</td><td>8 (89)</td></tr><tr><td>Sex</td><td></td></tr><tr><td>Man</td><td>6 (67)</td></tr><tr><td>Female</td><td>3 (33)</td></tr><tr><td>PS</td><td></td></... | <table><tr><td>No of patients with G0-1 RP (%)</td><td>p value</td></tr><tr><td></td><td>0.074</td></tr><tr><td>25 (45)</td><td></td></tr><tr><td>31 (55)</td><td></td></tr><tr><td></td><td>0.392</td></tr><tr><td>45 (80)</td><td></td></tr><tr><td>11 (20)</td><td></td></tr><tr><td></td><td>0.458</td></tr><tr><td>53 (95)<... |
c7c8b07f56bc36ac1de352ec1407cc9c32708b3694a0f96011265927b2c0b0ac.png | complex | <table><tr><td>Dose (mg/cm<sup>2</sup>)</td><td>#</td><td colspan="4">Mortality record for applied pests</td></tr><tr><td></td><td></td><td>Record after 24 hours</td><td>Average ± SD record after 24 hours</td><td>Record after 48 hours</td><td>Average ± SD record after 48 hours</td></tr><tr><td>1.77</td><td>10... | <table><tr><td>Dose (mg/cm2)</td><td>#</td><td colspan="4">Mortality record for applied pests</td></tr><tr><td></td><td></td><td>Record after 24 hours</td><td>Average ± SD record after 24 hours</td><td>Record after 48 hours</td><td>Average ± SD record after 48 hours</td></tr><tr><td>1.77</td><td>10</td><td>10</td><td>9... | <table><tr><td>Dose (mg/cm2)</td><td>#</td><td colspan="4">Mortality record for applied pests</td></tr><tr><td></td><td></td><td>Record after 24 hours</td><td>Average ± SD record after 24 hours</td><td>Record after 48 hours</td><td>Average ± SD record after 48 hours</td></tr><tr><td>1.77</td><td>10</td><td>10</td><td r... |
35ef44738842c10a84d539744e9b43a58c1edb57b415cc7ce9d21c8a20b83bc5.png | simple | <table><tr><td>Variables</td><td>Unstandardised coefficients (B)</td><td>S.E</td><td>Standardised coefficients (Beta)</td><td>P value</td></tr><tr><td>Age</td><td>− 0.020</td><td>0.017</td><td>− 0.066</td><td>0.241</td></tr><tr><td>Marital status</td><td>0.052</td><td>0.041</td><td>0.077</td><td>0.205</td><... | <table><tr><td>Variables</td><td>Unstandardised coefficients (B)</td><td>S.E</td><td>Standardised coefficients (Beta)</td><td>P value</td></tr><tr><td>Age</td><td>− 0.020</td><td>0.017</td><td>− 0.066</td><td>0.241</td></tr><tr><td>Marital status</td><td>0.052</td><td>0.041</td><td>0.077</td><td>0.205</td></tr><tr><td>... | <table><tr><td>Variables</td><td>Unstandardised coefficients (B)</td><td>S.E</td><td>Standardised coefficients (Beta)</td><td>P value</td></tr><tr><td>Pain severity score</td><td>− 0.011</td><td>0.002</td><td>− 0.353</td><td>< 0.001</td></tr><tr><td>Pain interference score</td><td>− 0.007</td><td>0.001</td><td>− 0.350<... |
7b849647d4a58575ee84dcb0e4afa9e9d8b64cda07823fb0461a9a26417a0ca9.png | complex | <table><tr><td></td><td></td><td colspan="2">Selection</td><td></td><td>Comparability</td><td></td><td>Outcome assessment</td><td></td><td></td></tr><tr><td>Author</td><td>Year</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>Score</td></tr><tr><td>Kon</td><td>2007</td><td>*</td><td>*</td><... | <table><tr><td></td><td></td><td colspan="2">Selection</td><td></td><td>Comparability</td><td></td><td>Outcome assessment</td><td></td><td></td></tr><tr><td>Author</td><td>Year</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>Score</td></tr><tr><td>Kon</td><td>2007</td><td>*</td><td>*</td><... | <table><tr><td>Zhao</td><td>2008</td><td>-</td><td>*</td><td>*</td><td>**</td><td>*</td><td>*</td><td>-</td><td>******</td></tr><tr><td>Reicher</td><td>2007</td><td>*</td><td>*</td><td>*</td><td>**</td><td>**</td><td>*</td><td>-</td><td>********</td></tr><tr><td>Vassiliades</td><td>2009</td><td>*</td><td>*</td><td>*</t... |
4686cc8e1b3bd8ce58b9ce0e462f1858102fc0c13c8baf99f31f360359eb7514.png | simple | <table><tr><td>Items</td><td>Normal controls</td><td>IPF</td><td>NSIP</td><td>HP</td><td>Sarcoidosis</td></tr><tr><td>No.</td><td>41</td><td>86</td><td>22</td><td>20</td><td>19</td></tr><tr><td>Age (year)</td><td>55(35–72)</td><td>67(59–75)*</td><td>60.1(39–70)</td><td>51.3(28–70)<sup>†</s... | <table><tr><td>Items</td><td>Normal controls</td><td>IPF</td><td>NSIP</td><td>HP</td><td>Sarcoidosis</td></tr><tr><td>No.</td><td>41</td><td>86</td><td>22</td><td>20</td><td>19</td></tr><tr><td>Age (year)</td><td>55(35–72)</td><td>67(59–75)*</td><td>60.1(39–70)</td><td>51.3(28–70)†</td><td>43.3 (28–69)†</td></tr><tr><t... | <table><tr><td>Neutrophils (×104/mL)</td><td>0.21 ± 0.047</td><td>1.45 ± 0.38*</td><td>2.31 ± 1.01*</td><td>3.14 ± 2.36*</td><td>0.45 ± 0.16*</td></tr><tr><td>Eosinophils (×104/mL)</td><td>0.02 ± 0.01</td><td>0.29 ± 0.07*</td><td>0.45 ± 0.14*</td><td>0.41 ± 0.19*</td><td>0.11 ± 0.07</td></tr><tr><td>Lymphocytes (×104/m... |
335ef491bd792128d8416aedc0a6114433507e40e70d94596c06bec8fd8914ff.png | simple | <table><tr><td>Kinases</td><td>Phosphatases</td><td>Growth factors</td><td>Cytokines</td><td>Transcription factors</td></tr><tr><td><i>Fgfr1</i></td><td><i>Acpp</i></td><td><i>Clec11a</i></td><td><i>Il10</i></td><td><i>Gata6</i></td></tr><tr><td><i>Pdk4</i></td><td><i>Dusp23</i></td><td><i>Gas6</i></td><td><i>Pf4</i></... | <table><tr><td>Kinases</td><td>Phosphatases</td><td>Growth factors</td><td>Cytokines</td><td>Transcription factors</td></tr><tr><td>Fgfr1</td><td>Acpp</td><td>Clec11a</td><td>Il10</td><td>Gata6</td></tr><tr><td>Pdk4</td><td>Dusp23</td><td>Gas6</td><td>Pf4</td><td>Lass4</td></tr><tr><td>Srms</td><td>Nt5e</td><td>Gdf6</t... | <table><tr><td>Kinases</td><td>Phosphatases</td><td>Growth factors</td><td>Cytokines</td><td>Transcription factors</td></tr><tr><td>Srk3</td><td>Pon1</td><td>Igf1</td><td>Wnt5a</td><td>Nfatc2</td></tr><tr><td></td><td>Ppap2b</td><td>Igf2</td><td></td><td>Per2</td></tr><tr><td></td><td></td><td>Inhbe</td><td></td><td>Ta... |
29a93c96c76b9190f222bad3606f537f172ae4bbbd90a74b19920161781e768d.png | simple | <table><tr><td>Variables<sup>a</sup></td><td>Preoperative</td><td>Discharge</td><td>6 months</td><td>1 year</td></tr><tr><td>Size 19 mm (n)</td><td>31</td><td>29</td><td>29</td><td>25</td></tr><tr><td> Peak gr, (mmHg)<sup>b</sup></td><td>76.1 ± 28.7</td><td>25.3 ± 9.5</td><td>24.1 ± 8.2</td><td>29.5 ... | <table><tr><td>Variablesa</td><td>Preoperative</td><td>Discharge</td><td>6 months</td><td>1 year</td></tr><tr><td>Size 19 mm (n)</td><td>31</td><td>29</td><td>29</td><td>25</td></tr><tr><td>Peak gr, (mmHg)b</td><td>76.1 ± 28.7</td><td>25.3 ± 9.5</td><td>24.1 ± 8.2</td><td>29.5 ± 11.0</td></tr><tr><td>Mean gr (mmHg)b</t... | <table><tr><td>I (g/m2)b</td><td>6.1 ± 22.8</td><td>.2 ± 52.3</td><td> ± 48.7</td><td>57.1</td></tr><tr><td>EF (%)</td><td>58.4 ± 7.9</td><td>56.4 ± 8.4</td><td>56.8 ± 8.2</td><td>55.9 ± 8.4</td></tr><tr><td>Size 23 mm (n)</td><td>58</td><td>56</td><td>56</td><td>53</td></tr><tr><td>Peak gr (mmHg)b</td><td>77.6 ± 29.9<... |
98e20c93834804c50058e05ff439ffef7ab9d060d27b5374ba04aca88611a2f3.png | complex | <table><tr><td>Gene ID</td><td>I_CN</td><td>I_0</td><td>Annotation</td></tr><tr><td colspan="4">Kinase</td></tr><tr><td> Unigene43155_xckb</td><td>D_U</td><td>F_F</td><td>Proline-rich receptor-like protein kinase PERK2</td></tr><tr><td> Unigene66089_xckb</td><td>U_D</td><td>F_F</td><td>G-type lectin S-receptor-like ser... | <table><tr><td>Gene ID</td><td>I_CN</td><td>I_0</td><td>Annotation</td></tr><tr><td colspan="4">Kinase</td></tr><tr><td></td><td></td><td></td><td>Proline-rich recepto</td></tr></table> | <table><tr><td>Gene ID</td><td>I_CN</td><td>I_0</td><td>Annotation</td></tr><tr><td>Unigene43155_xckb</td><td>D_U</td><td>F_F</td><td>r-like protein kinase PERK2</td></tr><tr><td>Unigene66089_xckb</td><td>U_D</td><td>F_F</td><td>G-type lectin S-receptor-like serine/threonine-protein kinase SD1-13</td></tr><tr><td>Unige... |
54e070f1480b59746d56af6f1c8d981409666238f4054b7239c4c1faec8f447a.png | simple | <table><tr><td>Diagnosis</td><td>Cases</td></tr><tr><td>Head injury</td><td>7</td></tr><tr><td>Skin lesions</td><td>5</td></tr><tr><td>Poisoning</td><td>4</td></tr><tr><td>Polytrauma</td><td>3</td></tr><tr><td>Others</td><td>2</td></tr></table> | <table><tr><td>Diagnosis</td><td>Cases</td></tr><tr><td>Head injury</td><td>7</td></tr><tr><td>S</td><td></td></tr></table> | <table><tr><td>Diagnosis</td><td>Cases</td></tr><tr><td>kin lesions</td><td>5</td></tr><tr><td>Poisoning</td><td>4</td></tr><tr><td>Polytrauma</td><td>3</td></tr><tr><td>Others</td><td>2</td></tr></table> |
3f252318011550c532575ace12b56de6b44ff0f67826b130d7cc40a2d6bea4c2.png | complex | <table><tr><td>Measure</td><td colspan="3">Early</td><td colspan="3">Late</td></tr><tr><td></td><td>Negative</td><td>Neutral</td><td>Positive</td><td>Negative</td><td>Neutral</td><td>Positive</td></tr><tr><td colspan="7">BEHAVIORAL</td></tr><tr><td>RT (ms)</td><td>666.06 (139.98)</td><td>668.84 (138.55)</td><td>667.24 ... | <table><tr><td>Measure</td><td colspan="3">Early</td><td colspan="3">Late</td></tr><tr><td></td><td>Negative</td><td>Neutral</td><td>Positive</td><td>Negative</td><td>Neutral</td><td>Positive</td></tr><tr><td colspan="7">BEHAVIORAL</td></tr><tr><td>RT (ms)</td><td>666.06 (139.98)</td><td>668.84 (138.55)</td><td>667.24 ... | <table><tr><td>Measure</td><td colspan="3">Early</td><td colspan="3">Late</td></tr><tr><td></td><td>Negative</td><td>Neutral</td><td>Positive</td><td>Negative</td><td>Neutral</td><td>Positive</td></tr><tr><td>ACC</td><td>0.94 (0.04)</td><td>0.96 (0.03)</td><td>0.95 (0.04)</td><td>0.96 (0.04)</td><td>0.95 (0.05)</td><td... |
97e20107cedcf3282aa86b9364c471ff1af528c1e0f7d2b539aea11bb502d559.png | complex | <table><tr><td>Plasmid</td><td colspan="5">Transfer frequency (transconjugant/recipient) (%)<sup>*</sup></td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>Mean ± <i>SD</i></td></tr><tr><td>pIJ303</td><td>93.83</td><td>103.18</td><td>101.03</td><td>95.90</td><td>95.83 ± 1.57</td></tr><tr><td>pI... | <table><tr><td>Plasmid</td><td colspan="5">Transfer frequency (transconjugant/recipient) (%)*</td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>Mean ± SD</td></tr><tr><td>pIJ303</td><td>93.83</td><td>103.18</td><td>101.03</td><td>95.90</td><td>95.83 ± 1.57</td></tr><tr><td>pIJ303ΔspdA2</td><td>97.49</td... | <table><tr><td>pIJ303-sps</td><td>95.43</td><td>96.95</td><td>92.74</td><td>98.16</td><td>96.35 ± 3.44</td></tr><tr><td>pIJ303spdA2c</td><td>96.55</td><td>104.19</td><td>95.87</td><td>106.21</td><td>98.30 ± 5.69</td></tr></table> |
f4c3a42226b868e280dcc19d78a0b6bb909a2d756cdf996eba86840d8584e1e5.png | simple | <table><tr><td>Kind of complications</td><td><i>n</i> = 20 (23.2 %)</td><td>Need for reoperation <i>n</i> = 19 (22.0 %)</td><td>Way the complication was handled</td></tr><tr><td>- Femoral shaft fracture</td><td>4 (4.6 %)</td><td>4 (4.6 %)</td><td>cerclage, cemented stem</td></tr><tr><td>- Calcar fracture</td><td>1 (1.2... | <table><tr><td>Kind of complications</td><td>n = 20 (23.2 %)</td><td>Need for reoperation n = 19 (22.0 %)</td><td>Way the complication was handled</td></tr><tr><td>- Femoral shaft fracture</td><td>4 (4.6 %)</td><td>4 (4.6 %)</td><td>cerclage, cemented stem</td></tr><tr><td>- Calcar fracture</td><td>1 (1.2 %)</td><td>1 ... | <table><tr><td>ection</td><td>2.3 %)</td><td>)</td><td>hange of head & inlay</td></tr><tr><td>- Hematoma</td><td>3 (3.5 %)</td><td>2 (2.3 %)</td><td>lavage, punction</td></tr><tr><td>- Thrombosis (%)</td><td>0 (0.0 %)</td><td>0 (0.0 %)</td><td>-</td></tr><tr><td>- Pulmonary embolism (%)</td><td>0 (0.0 %)</td><td>0 (0.0... |
e095678724d2022e64d896eee392d8b5c1d5324b8dd5e4614c2b3fe7cd2411f4.png | complex | <table><tr><td></td><td></td><td colspan="4">Cortisol</td><td colspan="4">DHEA</td></tr><tr><td></td><td></td><td colspan="2">IBS</td><td colspan="2">Control</td><td colspan="2">IBS</td><td colspan="2">Control</td></tr><tr><td>Day 1</td><td>Time 1</td><td>2.93</td><td>(0.29)</td><td>2.68</td><td>(0.24)</td><td>1.09</td... | <table><tr><td></td><td></td><td colspan="4">Cortisol</td><td colspan="4">DHEA</td></tr><tr><td></td><td></td><td colspan="2">IBS</td><td colspan="2">Control</td><td colspan="2">IBS</td><td colspan="2">Control</td></tr><tr><td>Day 1</td><td>Time 1</td><td>2.93</td><td>(0.29)</td><td>2.68</td><td>(0.24)</td><td>1.09</td... | <table><tr><td></td><td></td><td colspan="4">Cortisol</td><td colspan="4">DHEA</td></tr><tr><td></td><td></td><td colspan="2">IBS</td><td colspan="2">Control</td><td colspan="2">IBS</td><td colspan="2">Control</td></tr><tr><td></td><td>ime 2</td><td></td><td></td><td></td><td>.24)</td><td>1.08</td><td>0.08)</td><td>4</... |
19e7036c12d9859476ea915f6cec67018e4166890fbfc74f4c73c291f57b9069.png | complex | <table><tr><td colspan="2">Demographic Data</td><td>Diabetes Medication</td><td>Frequency</td></tr><tr><td>Male (%)</td><td>44 (61)</td><td>OHA</td><td>39</td></tr><tr><td>Female (%)</td><td>28 (39)</td><td>Insulin</td><td>7</td></tr><tr><td>Mean age</td><td>56</td><td>OHA + Insulin</td><td>18</td></tr><tr><td>Median a... | <table><tr><td colspan="2">Demographic Data</td><td>Diabetes Medication</td><td>Frequency</td></tr><tr><td>Male (%)</td><td>44 (61)</td><td>OHA</td><td>39</td></tr><tr><td>Female (%)</td><td>28 (39)</td><td>Insulin</td><td>7</td></tr><tr><td>Mean age</td><td>56</td><td>OHA + Insulin</td><td>18</td></tr><tr><td>Median a... | <table><tr><td colspan="2">Demographic Data</td><td>Diabetes Medication</td><td>Frequency</td></tr><tr><td>Mean BMI</td><td>39</td><td>HbA1c</td><td>(mmol/mol)</td></tr><tr><td>Median BMI</td><td>39</td><td>Mean HbA1c</td><td>67</td></tr><tr><td></td><td></td><td>Median Hb A1c</td><td>57</td></tr></table> |
ecf29b7ed3fa6c9cb5b354ddd8ab003945960126cde14fe57ca3718319c922ae.png | simple | <table><tr><td></td><td>National average</td><td>Less than $25,000</td><td>$25,000 to $34,999</td><td>$35,000 to $49,999</td><td>$50,000 to $74,999</td><td>$75,000 to $99,999</td><td>$100,000 or more</td></tr><tr><td><i>They are being harmed now</i></td><td>38</td><td>46</td><td>45</td><td>34</td><td>38</td><td>32</td>... | <table><tr><td></td><td>National average</td><td>Less than $25,000</td><td>$25,000 to $34,999</td><td>$35,000 to $49,999</td><td>$50,000 to $74,999</td><td>$75,000 to $99,999</td><td>$100,000 or more</td></tr><tr><td>They are being harmed now</td><td>38</td><td>46</td><td>45</td><td>34</td><td>38</td><td>32</td><td>33<... | <table><tr><td>χ2, p < 0.01; n = 2,073</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> |
4c0f3bb50b42e6ea4feb5cdf51637ff452f2d826e0cda1bb69407ee4df8a8fdf.png | complex | <table><tr><td rowspan="2">Natural populations</td><td rowspan="2">Year (number of accessions)</td><td colspan="2"><i>TaFlo2-A1a</i>Mean ± SE<sup>a</sup> (number of accessions)</td><td colspan="2"><i>TaFlo2-A1b</i>Mean ± SE (number of accessions)</td><td colspan="2">Mean difference ± SE</td><td rowspan="... | <table><tr><td rowspan="2">Natural populations</td><td rowspan="2">Year (number of accessions)</td><td colspan="2">TaFlo2-A1aMean ± SEa (number of accessions)</td><td colspan="2">TaFlo2-A1bMean ± SE (number of accessions)</td><td colspan="2">Mean difference ± SE</td><td rowspan="2">PVE (%)b TGW</td></tr><tr><td>TGW</td... | <table><tr><td rowspan="3">Chinese Micro Core Collection</td><td>2002 (137)</td><td>33.6 ± 0.54(98)</td><td>50.8 ± 1.2(98)</td><td>40.6 ± 1.2(39)</td><td>49.7 ± 1.5(39)</td><td>7.0 ± 1.1**</td><td>1.06 ± 2.1ns</td><td>6.19</td></tr><tr><td>2005 (169)</td><td>30.7 ± 0.52(128)</td><td>43.1 ± 0.8(128)</td><td>38.5 ± 1.1(4... |
c6811e52ba867e8638f30432767873efda85b1a793989d6bef409b4d8fe03bad.png | simple | <table><tr><td>Test</td><td>Occlusive patch (means)</td><td>Scotogenic lens (means)</td><td>Significance (K–S test), p value</td></tr><tr><td>Symptom control</td><td>9.73</td><td>9.27</td><td>0.985</td></tr><tr><td>Comfort</td><td>4.36</td><td>7.45</td><td>0.047</td></tr><tr><td>Aesthetics</td><td>2.00</td><td>9.... | <table><tr><td>Test</td><td>Occlusive patch (means)</td><td>Scotogenic lens (means)</td><td>Significance (K–S test), p value</td></tr><tr><td>Symptom control</td><td>9.73</td><td>9.27</td><td>0.985</td></tr><tr><td>Comfort</td><td>4.36</td><td>7.45</td><td>0.047</td></tr></table> | <table><tr><td>Test</td><td>Occlusive patch (means)</td><td>Scotogenic lens (means)</td><td>Significance (K–S test), p value</td></tr><tr><td>Aesthetics</td><td>2.00</td><td>9.45</td><td><0.001</td></tr><tr><td>Overall assessment</td><td>4.18</td><td>8.54</td><td><0.001</td></tr></table> |
4b9d27283901f65ba377d0682b6fc72d39501679f680807c7d60f4b2d9602c08.png | complex | <table><tr><td></td><td colspan="5">% of <i>|P</i>|</td></tr><tr><td># of ops as% of <i>n</i></td><td>Method</td><td>0</td><td>≤ 15%</td><td>≤ 20%</td><td>≤ 50%</td></tr><tr><td></td><td>1</td><td>97</td><td>97</td><td>97</td><td>100</td></tr><tr><td>10</td><td>2</td><td>97</td><td>97</td><td>97</td><... | <table><tr><td></td></tr><tr><td># of ops as% of n</td></tr><tr><td></td></tr><tr><td>10</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>15</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>20</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>25</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>29</td></t... | <table><tr><td colspan="5">% of |P|</td></tr><tr><td>Method</td><td>0</td><td>≤ 15%</td><td>≤ 20%</td><td>≤ 50%</td></tr><tr><td>1</td><td>97</td><td>97</td><td>97</td><td>100</td></tr><tr><td>2</td><td>97</td><td>97</td><td>97</td><td>100</td></tr><tr><td>3</td><td>96</td><td>96</td><td>96</td><td>99</td></tr><tr><td>... |
77a3b180132c795cce75623505886ee1e1f3d80f6b6eecbb98829a43608d8dbd.png | complex | <table><tr><td>Assays</td><td>Treatment Group</td><td>MeanCFU Counts</td><td colspan="4">Treatment Effect Group</td></tr><tr><td>CFU-GM</td><td>N</td><td>79.3</td><td>A</td><td></td><td></td><td></td></tr><tr><td></td><td>APS</td><td>52.3</td><td></td><td>B</td><td></td><td></td></tr><tr><td></td><td>TPO</td><td>50.0</... | <table><tr><td>Assays</td><td>Treatment Group</td><td>MeanCFU Counts</td><td colspan="3">Treatment Effect Group</td></tr><tr><td>CFU-GM</td><td>N</td><td>79.3</td><td>A</td><td></td><td></td></tr><tr><td></td><td>APS</td><td>52.3</td><td></td><td>B</td><td></td></tr><tr><td></td><td>TPO</td><td>50.0</td><td></td><td>B<... | <table><tr><td>Treatment Effect Group</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>D</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><t... |
c682ab8df4df694ff1dda0518eb27b3ae4004519f15e44061a97896be062d493.png | complex | <table><tr><td>Diets<sup>1</sup></td><td>Normal (%)</td><td colspan="4">Degree of Steatosis<sup>2</sup></td></tr><tr><td></td><td></td><td>< 5%</td><td>5-33%</td><td>33-6%</td><td>> 66%</td></tr><tr><td>CNC</td><td>100</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CC</td><td></td><td>40</td><td>-</td><... | <table><tr><td>Diets1</td><td>Normal (%)</td><td colspan="4">Degree of Steatosis2</td></tr></table> | <table><tr><td></td><td></td><td>< 5%</td><td>5-33%</td><td>33-6%</td><td>> 66%</td></tr><tr><td>CNC</td><td>100</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CC</td><td></td><td>40</td><td>-</td><td>20</td><td>40</td></tr><tr><td>LWS50</td><td>100</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>CS5... |
210214df48f1f95bda3f5dad79c0c9e7c8e852887f574d51dfd9f9fc2bc000a4.png | simple | <table><tr><td>Case</td><td>Age</td><td>Disease recurrence</td><td>Presence of metastasis*</td><td>Follow-up (months)</td><td>Life status</td></tr><tr><td>1</td><td>41</td><td>No</td><td>No</td><td>64</td><td>Alive</td></tr><tr><td>2</td><td>37</td><td>No</td><td>Yes</td><td>22</td><td>Alive</td></tr><tr><td>3</td><td>... | <table><tr><td>Case</td><td>Age</td><td>Disease recurrence</td><td>Presence of metastasis*</td><td>Follow-up (months)</td><td>Life status</td></tr><tr><td>1</td><td>41</td><td>No</td><td>No</td><td>64</td><td>Alive</td></tr><tr><td>2</td><td>37</td><td>No</td><td>Yes</td><td>22</td><td>Alive</td></tr><tr><td>3</td><td>... | <table><tr><td>Case</td><td>Age</td><td>Disease recurrence</td><td>Presence of metastasis*</td><td>Follow-up (months)</td><td>Life status</td></tr><tr><td>27</td><td>24</td><td>No</td><td>Yes</td><td>6</td><td>Alive</td></tr><tr><td>28</td><td>48</td><td>No</td><td>Yes</td><td>NI</td><td>Dead</td></tr><tr><td>29</td><t... |
2d125cf7f0aa01bcc31a55fd90c327dabe0ecd53f72b8f083eec8d39a7547202.png | simple | <table><tr><td></td><td>Prior to replacement (RR*, 95% CI)</td><td>Subsequent to replacement(RR, 95% CI)</td></tr><tr><td>All Outdoor Injuries</td><td>1.65 (1.50-1.82)</td><td>2.07 (1.91-2.24)</td></tr><tr><td>Non-equipment injuries</td><td>1.68 (1.50-1.89)</td><td>2.41 (2.20-2.64)</td></tr><tr><td>Equipment-related in... | <table><tr><td></td><td>Prior to replacement (RR*, 95% CI)</td><td>Subsequent to replacement(RR, 95% CI)</td></tr><tr><td>All Outdoor Injuries</td><td>1.65 (1.50-1.82)</td><td>2.07 (1.91-2.24)</td></tr></table> | <table><tr><td></td><td>Prior to replacement (RR*, 95% CI)</td><td>Subsequent to replacement(RR, 95% CI)</td></tr><tr><td>Non-equipment injuries</td><td>1.68 (1.50-1.89)</td><td>2.41 (2.20-2.64)</td></tr><tr><td>Equipment-related injuries</td><td>1.52 (1.24-1.86)</td><td>1.13 (0.95-1.32)</td></tr></table> |
5e85705dbbeef4ab6b39cf159b16e0d4d427ef630803e7b3ed21d9a66646f9c1.png | complex | <table><tr><td></td><td colspan="3">KwaZulu-Natal (KZN)</td><td colspan="3">Other South Africa (Other SA)</td></tr><tr><td></td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td></tr><tr><td></td><td></td><td>AIDS</td><td>No AIDS</td><td></td><td>AID... | <table><tr><td></td><td colspan="3">KwaZulu-Natal (KZN)</td><td colspan="3">Other South Africa (Other SA)</td></tr><tr><td></td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td></tr><tr><td></td><td></td><td>AIDS</td><td>No AIDS</td><td></td><td>AID... | <table><tr><td></td><td colspan="3">KwaZulu-Natal (KZN)</td><td colspan="3">Other South Africa (Other SA)</td></tr><tr><td></td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td><td>Initial, 2002</td><td colspan="2">Annual growth (%)</td></tr><tr><td></td><td></td><td>AIDS</td><td>No AIDS</td><td></td><td>AID... |
19819d8b6b115a6ab508c6ebb67aa2f9e8d85940bf4a44ecfe0fba0b69701958.png | simple | <table><tr><td>Polar Bear Scaffolds</td><td>5′ LTR Location</td><td>3′ LTR Location</td><td>Overall Mean K2P Distance</td><td>Age Estimation Mya</td></tr><tr><td>Scaffold 1</td><td>66,674,296–66,674,797</td><td>66,681,308–66,681,790</td><td>0.002</td><td>0.625</td></tr><tr><td>Scaffold 7</td><td... | <table><tr><td>Polar Bear Scaffolds</td><td>5′ LTR Location</td><td>3′ LTR Location</td><td>Overall Mean K2P Distance</td><td>Age Estimation Mya</td></tr></table> | <table><tr><td>Scaffold 1</td><td>66,674,296–66,674,797</td><td>66,681,308–66,681,790</td><td>0.002</td><td>0.625</td></tr><tr><td>Scaffold 7</td><td>30,626,500–30,627,187</td><td>30,633,692–30,634,278</td><td>0.007</td><td>2.1875</td></tr><tr><td>Scaffold 162</td><td>7152–7643</td><td>13,824–14,441</td><td>ND</td><td>... |
f64c325b3035d88ad2adecef7edb51f4b608a7cd1348138a50473927918d3e73.png | complex | <table><tr><td> </td><td> </td><td> </td><td> </td><td colspan="2">Cardiac infarction</td><td>Crude estimate</td><td>Age-adjusted estimate</td></tr><tr><td> </td><td>Age (years)</td><td>Gender</td><td>Total</td><td>Yes</td><td>No</td><td>OR (95% CI), <i>p</i>-value</td><td>OR (95% CI), <i>p</i>-value</td></tr><tr><td>i... | <table><tr><td></td><td></td><td></td><td></td><td colspan="2">Cardiac infarction</td><td>Crude estimate</td><td>Age-adjusted estimate</td></tr><tr><td></td><td>Age (years)</td><td>Gender</td><td>Total</td><td>Yes</td><td>No</td><td>OR (95% CI), p-value</td><td>OR (95% CI), p-value</td></tr><tr><td></td><td>≥ 35</td><t... | <table><tr><td>iNPH</td><td> - 70</td><td>male</td><td>95</td><td>)</td><td>9%)</td><td>8 (0.7 – 11.6), NS</td><td>.4), NS</td></tr><tr><td>HUNT3</td><td>≥ 35 - 70</td><td>Female</td><td>18,988</td><td>143 (0.8%)</td><td>18,845 (99.2%)</td><td></td><td></td></tr><tr><td>iNPH</td><td>≥ 35 - 70</td><td>Male</td><td>81</t... |
01c0065d64387e586044d08fc5a615ed1006fc0849a0e14d59a76110bcc61af6.png | complex | <table><tr><td>S-RAMM items</td><td>AUC</td><td colspan="2">95% confidence interval of AUC</td><td>p</td><td>Odds ratio</td><td colspan="2">95% confidence interval of OR</td><td>p</td></tr><tr><td> </td><td> </td><td>Lower</td><td>Upper</td><td> </td><td> </td><td>Lower</td><td>Upper</td><td> </td></tr><tr><td>B1 Histo... | <table><tr><td>S-RAMM items</td><td>AUC</td><td colspan="2">95% confidence interval of AUC</td><td>p</td><td>Odds ratio</td><td colspan="2">95% confidence interval of OR</td><td>p</td></tr></table> | <table><tr><td></td><td></td><td>Lower</td><td>Upper</td><td></td><td></td><td>Lower</td><td>Upper</td><td></td></tr><tr><td>B1 History of deliberate self harm</td><td>0.474</td><td>0.275</td><td>0.672</td><td>0.783</td><td>1.186</td><td>0.582</td><td>2.416</td><td>0.639</td></tr><tr><td>B2 Seriousness of previous suic... |
58e850c65ae7dad636eaafcab95bf5dba039b02bebe991d3faf54cc851041199.png | complex | <table><tr><td></td><td>50–64 yrs.(<i>N</i> = 1,021,648)n (%)</td><td>≥ 65 yrs.(<i>N</i> = 1,011,817)N (%)</td><td>ODDS RATIO(OR)OR 95%CI</td></tr><tr><td colspan="4">Immunocompromising conditions</td></tr><tr><td> Primary immunodeficiency</td><td>295 (<0.1)</td><td>294 (<0.1)</td><td>1.01 (0.85–... | <table><tr><td></td></tr><tr><td>Immunocompromising conditions</td></tr><tr><td>Primary immunodeficiency</td></tr><tr><td>HIV infection</td></tr><tr><td>Nephrotic syndrome</td></tr><tr><td>Severe renal failure (GFR < 30)</td></tr><tr><td>Bone marrow trasplantation</td></tr><tr><td>Recent cancer</td></tr><tr><td>Immunos... | <table><tr><td>50–64 yrs.(N = 1,021,648)n (%)</td><td>≥ 65 yrs.(N = 1,011,817)N (%)</td><td>ODDS RATIO(OR)OR 95%CI</td></tr><tr><td colspan="3">Immunocompromising conditions</td></tr><tr><td>295 (<0.1)</td><td>294 (<0.1)</td><td>1.01 (0.85–1.19)</td></tr><tr><td>2825 (0.3)</td><td>449 (<0.1)</td><td>0.16 (0.14–0.18)</t... |
29850512d4a092266975c8be534b586f5d12de81b21c3862467c265d5c1e08e5.png | complex | <table><tr><td colspan="2">Recurrence</td></tr><tr><td>Intrahepatic recurrence</td><td>222 (76.6%)</td></tr><tr><td>Extrahepatic recurrence</td><td>68 (23.4%)</td></tr><tr><td>Main treatment for recurrence</td><td> </td></tr><tr><td>Transplantation</td><td>10 (3.4%)</td></tr><tr><td>Repeat resection</td><td>29 (9.8%)</... | <table><tr><td colspan="2">Recurrence</td></tr><tr><td>Intrahepatic recurrence</td><td>222 (76.6%)</td></tr><tr><td>Extrahepatic recurrence</td><td>68 (23.4%)</td></tr><tr><td>Main treatment for recurrence</td><td></td></tr><tr><td>Transplantation</td><td>10 (3.4%)</td></tr><tr><td>Repeat resection</td><td>29 (9.8%)</t... | <table><tr><td>TACE</td><td>172 (58.1%)</td></tr><tr><td>Chemotherapy</td><td>26 (4.3%)</td></tr><tr><td>Radiation therapy</td><td>16 (5.4%)</td></tr><tr><td>Cause of death</td><td></td></tr><tr><td>Recurrent HCC</td><td>182 (80.9%)</td></tr><tr><td>Complication of liver cirrhosis without recurrence</td><td>25 (11.1%)<... |
308dfcbf85128d66f195045bfe07fa8f91cd76706ba80114eda998b5f0e8eca1.png | simple | <table><tr><td></td><td>Normoxic</td><td>Hypoxic</td><td>Hypoxic + CPP</td></tr><tr><td>Alkaline Phosphatase</td><td>179 <underline>+</underline> 20</td><td>195 <underline>+</underline> 31</td><td>176 <underline>+</underline> 16</td></tr><tr><td>ALT</td><td>25 <underline>+</underline> 4</td><td>30 <underline>+</underli... | <table><tr><td></td><td>Normoxic</td><td>Hypoxic</td><td>Hypoxic + CPP</td></tr><tr><td>Alkaline Phosphatase</td><td>179 + 20</td><td>195 + 31</td><td>176 + 16</td></tr><tr><td>ALT</td><td>25 + 4</td><td>30 + 10</td><td>33 + 6</td></tr><tr><td>AST</td><td>48 + 3</td><td>73 + 8 *</td><td>81 + 8 *</td></tr><tr><td>Creati... | <table><tr><td>ne Kinase</td><td> + 46</td><td>36 + 90</td><td>225 + 38</td></tr><tr><td>GGT</td><td>2.0 + 0.0</td><td>3.0 + 0.0</td><td>2.4 + 0.6</td></tr><tr><td>Albumin</td><td>2.9 + 0.1</td><td>2.9 + 0.2</td><td>2.8 + 0.1</td></tr><tr><td>Total Protein</td><td>5.6 + 0.2</td><td>5.2 + 0.2</td><td>5.0 + 0.1</td></tr>... |
1018d80e45c79acc6fe000a4cc17e8e194bbe6d1fecb9294eb240647945ada50.png | complex | <table><tr><td rowspan="3">Transient neurological symptoms</td><td colspan="8">Age (years)</td></tr><tr><td colspan="2">All</td><td colspan="2">65–74 (N=3657)</td><td colspan="2">75–84 (N=2618)</td><td colspan="2">85+ (N=473)</td></tr><tr><td>N</td><td>Per cent*</td><td>N</td><td>Per cent*</td><td>N</td><td... | <table><tr><td rowspan="3">Transient neurological symptoms</td><td colspan="8">Age (years)</td></tr><tr><td colspan="2">All</td><td colspan="2">65–74 (N=3657)</td><td colspan="2">75–84 (N=2618)</td><td colspan="2">85+ (N=473)</td></tr><tr><td>N</td><td>Per cent*</td><td>N</td><td>Per cent*</td><td>N</td><td>Per cent*</... | <table><tr><td>Loss of speech</td><td>149</td><td>2.1</td><td>55</td><td>1.5</td><td>84</td><td>3.3</td><td>10</td><td>2.0</td></tr><tr><td>Weakness</td><td>239</td><td>3.7</td><td>117</td><td>3.4</td><td>106</td><td>4.1</td><td>16</td><td>3.4</td></tr><tr><td>Loss of sight</td><td>410</td><td>6.3</td><td>214</td><td>6... |
b8179b6ea0e6066b1dd6587ac3d1ec86614c230aa6cd88c04fd5cee921445154.png | simple | <table><tr><td></td><td>Subjects with DLCO</td><td>Subjects without DLCO</td><td>p-value</td></tr><tr><td>Sample size</td><td>53</td><td>20</td><td>-</td></tr><tr><td>Age, years*</td><td>64 (1)</td><td>61 (2)</td><td>0.16</td></tr><tr><td>Sex, M/F</td><td>32/21</td><td>10/10</td><td>0.43</td></tr><tr><td>Pack years*</t... | <table><tr><td></td><td>Subjects with DLCO</td><td>Subjects without DLCO</td><td>p-value</td></tr><tr><td>Sample size</td><td>53</td><td>20</td><td>-</td></tr><tr><td>Age, years*</td><td>64 (1)</td><td>61 (2)</td><td>0.16</td></tr></table> | <table><tr><td></td><td>Subjects with DLCO</td><td>Subjects without DLCO</td><td>p-value</td></tr><tr><td>Sex, M/F</td><td>32/21</td><td>10/10</td><td>0.43</td></tr><tr><td>Pack years*</td><td>54 (3)</td><td>49 (5)</td><td>0.49</td></tr><tr><td>Current smokers (%)</td><td>15 (28)</td><td>4 (20)</td><td>0.48</td></tr><t... |
4abe8c6616be38fa8469156ff40049b4f7e1141805fbb181b558bc9fbfef1a52.png | simple | <table><tr><td></td><td>Targets</td><td><|P|></td><td><|N|></td><td>dDFIRE</td><td>OPUS_PSP</td><td>RWplus</td><td>GOAP</td><td>ROTAS</td></tr><tr><td>4state_reduced</td><td>7</td><td>195</td><td>468</td><td>0.86</td><td>0.80</td><td>0.81</td><td>0.91</td><td>0.92</td></tr><tr><td>fisa</td><td>2</td><td>47<... | <table><tr><td></td><td>Targets</td><td><|P|></td><td><|N|></td><td>dDFIRE</td><td>OPUS_PSP</td><td>RWplus</td><td>GOAP</td><td>ROTAS</td></tr></table> | <table><tr><td>4state_reduced</td><td>7</td><td>195</td><td>468</td><td>0.86</td><td>0.80</td><td>0.81</td><td>0.91</td><td>0.92</td></tr><tr><td>fisa</td><td>2</td><td>47</td><td>453</td><td>0.79</td><td>0.60</td><td>0.79</td><td>0.79</td><td>0.77</td></tr><tr><td>lmds</td><td>2</td><td>60</td><td>439</td><td>0.74</td... |
2fefab9152f7d70d23f3441ceedebc9bc063b81233ca2ec98e9dc273b49e608c.png | simple | <table><tr><td>#</td><td>Size</td><td>GO-ID</td><td>GO-Term</td><td><i>p</i>-value</td><td>N%</td></tr><tr><td>1</td><td>17</td><td>GO:0030880</td><td>RNA polymerase complex</td><td>3.30986E-39</td><td>100.0 %</td></tr><tr><td>2</td><td>8</td><td>GO:0044428</td><td>Nuclear part</td><td>3.70274E-05</td><td>100.0 %</td><... | <table><tr><td>#</td><td>Size</td><td>GO-ID</td><td>GO-Term</td><td>p-value</td><td>N%</td></tr><tr><td>1</td><td>17</td><td>GO:0030880</td><td>RNA polymerase complex</td><td>3.30986E-39</td><td>100.0 %</td></tr><tr><td>2</td><td>8</td><td>GO:0044428</td><td>Nuclear part</td><td>3.70274E-05</td><td>100.0 %</td></tr><tr... | <table><tr><td></td><td></td><td>0005634</td><td>eus</td><td>7E-10</td><td></td></tr><tr><td>12</td><td>10</td><td>GO:0044425</td><td>Membrane part</td><td>4.18992E-10</td><td>100.0 %</td></tr><tr><td>13</td><td>5</td><td>GO:0035097</td><td>Histone methyl–transferase complex</td><td>1.31389E-11</td><td>100.0 %</td></tr... |
754f539ca45e571e2fc3aa26360e07909c407541a5e8c30e6057674842cfa07a.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">ER-β</td><td colspan="3">PR</td></tr><tr><td>(+)</td><td>(-)</td><td><i>P</i></td><td>(+)</td><td>(-)</td><td><i>P</i></td></tr><tr><td>Age (years)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td> ≥50</td><td>16</td><td>22</td><td>0.706</td><td>16</t... | <table><tr><td rowspan="2"></td><td colspan="3">ER-β</td><td colspan="3">PR</td></tr><tr><td>(+)</td><td>(-)</td><td>P</td><td>(+)</td><td>(-)</td><td>P</td></tr><tr><td>Age (years)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td>≥50</td><td>16</td><td>22</td><td>0.706</td><td>16</td><td>22</td><td>0.107</td... | <table><tr><td>Normal</td><td>58</td><td>61</td><td>0.059</td><td>38</td><td>81</td><td>0.859</td></tr><tr><td>>5</td><td>10</td><td>23</td><td></td><td>10</td><td>23</td><td></td></tr><tr><td>Serum CA19-9 (U/mL)</td><td colspan="3"></td><td colspan="3"></td></tr><tr><td>Normal</td><td>43</td><td>53</td><td>0.986</td><... |
f61770437016849dc0c648e2db6d362731167b180ec03501736a77dd9d7a38ed.png | complex | <table><tr><td rowspan="2">Parameters</td><td colspan="2">Present study</td><td rowspan="2">Verkerk et al. [16]</td><td rowspan="2">Tüysüz et al. [15]</td></tr><tr><td>Ind IV:3</td><td>Ind IV:4</td></tr><tr><td>Gender</td><td>M</td><td>M</td><td>3F/2M</td><td>3F/1M</td></tr><tr><td>Age at last examination (... | <table><tr><td rowspan="2">Parameters</td><td colspan="2">Present study</td><td rowspan="2">Verkerk et al. [16]</td><td rowspan="2">Tüysüz et al. [15]</td></tr><tr><td>Ind IV:3</td><td>Ind IV:4</td></tr><tr><td>Gender</td><td>M</td><td>M</td><td>3F/2M</td><td>3F/1M</td></tr><tr><td>Age at last examination (y.)</td><t... | <table><tr><td rowspan="2">Parameters</td><td>Present study</td><td rowspan="2">Verkerk et al. [16]</td><td rowspan="2">Tüysüz et al. [15]</td></tr><tr><td>Ind IV:3</td></tr><tr><td>Widened lateral ventricles</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Thin splenium of the CC</td><td>+</td><td>+</td><td>+</td></tr... |
2a12d0ca480fc6fa2cfba15fdfd8982dac222b8cf0ecc4b6ed444dc24ee61aa7.png | simple | <table><tr><td>Characteristic</td><td>Value</td><td>%</td></tr><tr><td>Age (years)</td><td></td><td></td></tr><tr><td>Range</td><td>30–87</td><td></td></tr><tr><td>Mean ± SD (range)</td><td>60.3±15.9</td><td></td></tr><tr><td>Gender, n</td><td></td><td></td></tr><tr><td>Male</td><td>62</td><td>51.2</td>... | <table><tr><td>Characteristic</td><td>Value</td><td>%</td></tr><tr><td>Age (years)</td><td></td><td></td></tr><tr><td>Range</td><td>30–87</td><td></td></tr><tr><td>Mean ± SD (range)</td><td>60.3±15.9</td><td></td></tr><tr><td>Gender, n</td><td></td><td></td></tr><tr><td>Male</td><td>62</td><td>51.2</td></tr><tr><td>Fem... | <table><tr><td>Without</td><td>50</td><td>41.3</td></tr></table> |
027fe55be37f5b45a9d9694e9dfcec248db0f73d1aa948aca70acc54767ed126.png | complex | <table><tr><td>Investigator</td><td>Patient</td><td>Total fibres</td><td>% COX positive</td><td>% Intermediate positive</td><td>% Intermediate negative</td><td>% COX negative</td></tr><tr><td rowspan="8">1</td><td>DYSF 1</td><td>1491</td><td>98.2%</td><td>1.8%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>DYSF 2</td><td>5... | <table><tr><td>Investigator</td><td>Patient</td></tr><tr><td rowspan="8">1</td><td>DYSF 1</td></tr><tr><td>DYSF 2</td></tr><tr><td>DYSF 3</td></tr><tr><td>DYSF 4</td></tr><tr><td>DYSF 5</td></tr><tr><td>DYSF 6</td></tr><tr><td>DYSF 7</td></tr><tr><td>DYSF 8</td></tr><tr><td rowspan="8">2</td><td>DYSF 1</td></tr><tr><td... | <table><tr><td>Total fibres</td><td>% COX positive</td><td>% Intermediate positive</td><td>% Intermediate negative</td><td>% COX negative</td></tr><tr><td>1491</td><td>98.2%</td><td>1.8%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>577</td><td>75.4%</td><td>18.4%</td><td>6.1%</td><td>0.1%</td></tr><tr><td>963</td><td>65.... |
b568ef25b154685f9682b62cf39aabdc6b849d4e08f47fc25ab30013930588dc.png | simple | <table><tr><td>Metagenome source</td><td>Sample</td><td>Metagenome type</td><td>Categories observed<sup>N</sup></td><td>Shannon diversity Index (H’)</td><td>Evenness (E)</td></tr><tr><td>This study</td><td>Cow 2202<sup>C</sup></td><td>Virome</td><td>20</td><td>2.192</td><td>0.732</td></tr><tr><td> </td><td>Cow 65... | <table><tr><td>Metagenome source</td><td>Sample</td><td>Metagenome type</td><td>Categories observedN</td><td>Shannon diversity Index (H’)</td><td>Evenness (E)</td></tr><tr><td>This study</td><td>Cow 2202C</td><td>Virome</td><td>20</td><td>2.192</td><td>0.732</td></tr><tr><td></td><td>Cow 657</td><td>Virome</td><td>21</... | <table><tr><td>Metagenome source</td><td>Sample</td><td>Metagenome type</td><td>Categories observedN</td><td>Shannon diversity Index (H’)</td><td>Evenness (E)</td></tr><tr><td></td><td>Cow 3060</td><td>Virome</td><td>16</td><td>2.150</td><td>0.775</td></tr><tr><td></td><td>Cow 4570</td><td>Virome</td><td>15</td><td>2.0... |
c208ddb354482909cfadb9f6cdf9b046f88ab56744ea76356f525cbeb5b8b696.png | complex | <table><tr><td> </td><td colspan="4">Group 1</td><td colspan="2">Group 2</td><td colspan="2">Group 3</td></tr><tr><td> </td><td>Relapsing- remitting MS</td><td>Primary progressive MS</td><td>Secondary progressive MS</td><td>Healthy controls</td><td>Pediatric onset MS</td><td>Pediatric healthy controls</td><td>Pre- rela... | <table><tr><td></td><td colspan="4">Group 1</td><td colspan="2">Group 2</td><td colspan="2">Group 3</td></tr><tr><td></td><td>Relapsing- remitting MS</td><td>Primary progressive MS</td><td>Secondary progressive MS</td><td>Healthy controls</td><td>Pediatric onset MS</td><td>Pediatric healthy controls</td><td>Pre- relaps... | <table><tr><td>N</td><td>20</td><td>13</td><td>12</td><td>48</td><td>12</td><td>10</td><td>18</td><td>11</td></tr><tr><td>Males N (%)</td><td>3 (15.0)</td><td>6 (46.2)</td><td>1 (8.3)</td><td>14 (29.2)</td><td>4 (33.3)</td><td>3 (30.0)</td><td>3 (16.7)</td><td>2 (18.2)</td></tr><tr><td>Age Mean (SD)</td><td>43.0 (8.9)<... |
4a7a5575f1752f0d63e7f3721da56b5b63bd49487e88e14a42bd284717fe2ef7.png | simple | <table><tr><td>Code</td><td>Test</td><td>Supported draft</td></tr><tr><td>INV_1_24</td><td>FISH/int</td><td>UMD (85%)</td></tr><tr><td>INV_1_53.3</td><td>FISH/int</td><td>UMD (94%)</td></tr><tr><td>INV_4_7.2</td><td>FISH/int</td><td>UMD (90%)</td></tr><tr><td>INV_7_103.2</td><td>FISH/int</td><td>UMD (96%)</td></tr><tr>... | <table><tr><td>Code</td><td>Test</td><td>Supported draft</td></tr><tr><td>INV_1_24</td><td>FISH/int</td><td>UMD (85%)</td></tr><tr><td>INV_1_53.3</td><td>FISH/int</td><td>UMD (94%)</td></tr><tr><td>INV_4_7.2</td><td>FISH/int</td><td>UMD (90%)</td></tr></table> | <table><tr><td>INV_7_103.2</td><td>FISH/int</td><td>UMD (96%)</td></tr><tr><td>INV_10_59.3</td><td>FISH/int</td><td>UMD (95%)</td></tr><tr><td>INV_14_32</td><td>FISH/int</td><td>UMD (73%)</td></tr><tr><td>INV_20_0</td><td>FISH/int</td><td>UMD (98%)</td></tr><tr><td>INV_23_0</td><td>FISH/met.</td><td>UMD</td></tr><tr><t... |
1210d5e5869a551e7a44c611a8c2022d4480327bedae7e2108a8b24fdb14602a.png | simple | <table><tr><td></td><td></td><td>Allpaths-LG/</td><td>Allpaths-LG/</td></tr><tr><td>Scaffold sequences</td><td>Allpaths-LG</td><td>Sspace/GapClose</td><td>Sspace/GapClose/Reapr</td></tr><tr><td>Number</td><td>57 815</td><td>16 090</td><td>13 206</td></tr><tr><td>Total size, without gaps, bp</td><td>469 049 393</td><td>... | <table><tr><td></td><td></td><td>Allpaths-LG/</td><td>Allpaths-LG/</td></tr><tr><td>Scaffold sequences</td><td>Allpaths-LG</td><td>Sspace/GapClose</td><td>Sspace/GapClose/Reapr</td></tr><tr><td>Number</td><td>57 815</td><td>16 090</td><td>13 206</td></tr><tr><td>Total size, without gaps, bp</td><td>469 049 393</td><td>... | <table><tr><td></td><td></td><td>Allpaths-LG/</td><td>Allpaths-LG/</td></tr><tr><td>Scaffold sequences</td><td>Allpaths-LG</td><td>Sspace/GapClose</td><td>Sspace/GapClose/Reapr</td></tr><tr><td>L50 count</td><td>2595</td><td>1792</td><td>1906</td></tr><tr><td>GC %</td><td>33.63</td><td>33.57</td><td>33.62</td></tr></ta... |
2a9ea923d66daf7a6c18ed94c09841e8e9a1e07a1950ed934ed23bab7eb534b6.png | simple | <table><tr><td>Process Type</td><td>processes</td><td>instances</td><td>Time</td><td>Total ($)</td></tr><tr><td>Blast</td><td>21945</td><td>100</td><td>40 hours 0 mins</td><td>$ 3,680</td></tr><tr><td>Ortholog Estimation</td><td>281160</td><td>100</td><td>28 hours 21 mins</td><td>$ 2,622</td></tr></table> | <table><tr><td>Process Type</td><td>processes</td><td>instances</td><td>Time</td><td>Total ($)</td></tr></table> | <table><tr><td>Blast</td><td>21945</td><td>100</td><td>40 hours 0 mins</td><td>$ 3,680</td></tr><tr><td>Ortholog Estimation</td><td>281160</td><td>100</td><td>28 hours 21 mins</td><td>$ 2,622</td></tr></table> |
17c62f4dc82e17268fe2fef5fc2091beb1cec2a00e5815160adfeac6b5adac52.png | complex | <table><tr><td></td><td>Odds ratio</td><td>95% Confidence interval</td><td><i>P</i> value</td></tr><tr><td colspan="4">Predictors of AKI</td></tr><tr><td>Log angiopoietin-2</td><td>4.41</td><td>2.02–9.63</td><td><0.0001</td></tr><tr><td>Log osteoprotegerin</td><td>1.98</td><td>1.02–3.82</td><td>0.043</td... | <table><tr><td></td><td>Odds ratio</td></tr><tr><td colspan="2">Predictors of AKI</td></tr><tr><td>Log angiopoietin-2</td><td>4.41</td></tr><tr><td>Log osteoprotegerin</td><td>1.98</td></tr><tr><td>Agea</td><td>1.07</td></tr><tr><td colspan="2">Predictor of severe malaria</td></tr><tr><td>Log angiopoietin-2</td><td>5.3... | <table><tr><td>95% Confidence interval</td><td>P value</td></tr><tr><td colspan="2">Predictors of AKI</td></tr><tr><td>2.02–9.63</td><td><0.0001</td></tr><tr><td>1.02–3.82</td><td>0.043</td></tr><tr><td>1.04–1.10</td><td><0.0001</td></tr><tr><td colspan="2">Predictor of severe malaria</td></tr><tr><td>2.01–14.25</td><t... |
5edb160ecf0f7e083502f59dfe6efa37ae269216eeef924398c01d8c050a42ec.png | simple | <table><tr><td>Treatment</td><td>N</td><td>Median</td><td>IQR</td><td>RR</td><td>95% CI</td><td>z value</td><td>p value</td></tr><tr><td>No insecticide</td><td>1054</td><td>47.0</td><td>22.0 – 110.3</td><td>45.0</td><td>[23.1, 87.8]</td><td>11.168</td><td>NA</td></tr><tr><td>Transfluthrin coils</td><td>737</td><t... | <table><tr><td>Treatment</td><td>N</td><td>Median</td><td>IQR</td><td>RR</td><td>95% CI</td><td>z value</td></tr><tr><td>No insecticide</td><td>1054</td><td>47.0</td><td>22.0 – 110.3</td><td>45.0</td><td>[23.1, 87.8]</td><td>11.168</td></tr><tr><td>Transfluthrin coils</td><td>737</td><td>71.0</td><td>28.0 – 92.5</td><t... | <table><tr><td>p value</td></tr><tr><td>NA</td></tr><tr><td>0.369</td></tr><tr><td>0.203</td></tr><tr><td>0.989</td></tr></table> |
72ffd32955bd080bdcb669989612c9193c57af1e5bd482f300495c0df4b26fa9.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Any enteric pathogen</td><td colspan="2"><i>Campylobacter</i> spp.</td><td colspan="2"><i>Giardia</i> spp.</td><td colspan="2">Pathogenic <i>Escherichia coli</i>†</td></tr><tr><td>PR (95% CI)</td><td><i>P</i> value</td><td>PR (95% CI)</td><td><i>P</i> value</td><td>... | <table><tr><td></td><td colspan="2">Any enteric pathogen</td><td colspan="2">Campylobacter spp.</td><td colspan="2">Giardia spp.</td><td colspan="2">Pathogenic Escherichia coli†</td></tr></table> | <table><tr><td></td><td>PR (95% CI)</td><td>P value</td><td>PR (95% CI)</td><td>P value</td><td>PR (95% CI)</td><td>P value</td><td>PR (95% CI)</td><td>P value</td></tr><tr><td>Neighborhood: Old Town</td><td>1.32 (0.50, 3.49)</td><td>0.57</td><td>1.91 (0.71, 5.14)</td><td>0.18</td><td>1.56 (0.48, 6.46)</td><td>0.45</td... |
cffe1cc850c2df600000995df6fbcaa58a4b1e13391b8ba60123565267ebe373.png | simple | <table><tr><td>Pathway</td><td>TF</td><td>miRNA</td></tr><tr><td>Activin</td><td>TP53</td><td>miR-143</td></tr><tr><td>AKT</td><td>MYC</td><td>miR-145</td></tr><tr><td>ALK</td><td>GATA4</td><td>miR-187</td></tr><tr><td>ATM</td><td>SMAD1</td><td>miR-296</td></tr><tr><td>BMI1</td><td>ESRRB</td><td>miR-301</td></tr><tr><t... | <table><tr><td>Pathway</td><td>TF</td><td>miRNA</td></tr><tr><td>Activin</td><td>TP53</td><td>miR-143</td></tr></table> | <table><tr><td>Pathway</td><td>TF</td><td>miRNA</td></tr><tr><td>AKT</td><td>MYC</td><td>miR-145</td></tr><tr><td>ALK</td><td>GATA4</td><td>miR-187</td></tr><tr><td>ATM</td><td>SMAD1</td><td>miR-296</td></tr><tr><td>BMI1</td><td>ESRRB</td><td>miR-301</td></tr><tr><td>BMP</td><td>SOX2</td><td>miR-21</td></tr><tr><td>Cel... |
1a5d6246c41a28bf747f5774fabd6d04440284310b3c81d90635e22cc8934db8.png | simple | <table><tr><td>Variable</td><td>Dextrose75 g</td><td>Dextrose150 g</td><td>Lipid33 g</td><td>Lipid66 g</td></tr><tr><td>Kilocalories</td><td>2023 ± 237</td><td>2354 ± 242</td><td>1983 ± 206</td><td>1789 ± 181</td></tr><tr><td>Protein (g)</td><td>92 ± 11</td><td>102 ± 9</td><td>95 ± 13... | <table><tr><td>Variable</td><td>Dextrose75 g</td><td>Dextrose150 g</td><td>Lipid33 g</td><td>Lipid66 g</td></tr><tr><td>Kilocalories</td><td>2023 ± 237</td><td>2354 ± 242</td><td>1983 ± 206</td><td>1789 ± 181</td></tr><tr><td>Protein (g)</td><td>92 ± 11</td><td>102 ± 9</td><td>95 ± 13</td><td>88 ± 16</td></tr><tr><td>C... | <table><tr><td>Variable</td><td>Dextrose75 g</td><td>Dextrose150 g</td><td>Lipid33 g</td><td>Lipid66 g</td></tr><tr><td>at (g)</td><td>72 ± 11</td><td>1 ± 12</td><td></td><td>9</td></tr><tr><td>Vitamin C (mg)</td><td>64 ± 26</td><td>47 ± 11</td><td>40 ± 7</td><td>51 ± 13</td></tr><tr><td>Vitamin E (mg)</td><td>4 ± 2</t... |
406632cca340e9288ce0f546c0d09ea97e6e3df0fcdaf6344d4f3a2c179d6075.png | complex | <table><tr><td rowspan="2">Parameter</td><td rowspan="2">Shams</td><td colspan="2">Exposure to AO nanowhiskers for:</td></tr><tr><td>2 wks</td><td>4 wks</td></tr><tr><td>Total cells/mouse, n x 10<sup>3</sup></td><td>74.0 ± 7.9</td><td>171.6 ± 19.7 **</td><td>440.3 ± 33.6 ***</td></tr><tr><td>Total protei... | <table><tr><td rowspan="2">Parameter</td><td rowspan="2">Shams</td><td colspan="2">Exposure to AO nanowhiskers for:</td></tr><tr><td>2 wks</td><td>4 wks</td></tr></table> | <table><tr><td>Total cells/mouse, n x 103</td><td>74.0 ± 7.9</td><td>171.6 ± 19.7 **</td><td>440.3 ± 33.6 ***</td></tr><tr><td>Total protein, μg/mL</td><td>107.7 ± 4.7</td><td>108.0 ± 1.5</td><td>101.2 ± 2.7</td></tr><tr><td>LDH activity, U/L</td><td>180 ± 18</td><td>146 ± 17</td><td>191 ± 10</td></tr></table> |
9d475d7c44f58bc41576169965a0c5ff5c1cd9e9fc49f68a24c154bd2b8be5f5.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="2">Cases</td><td colspan="2">Controls</td><td rowspan="2">P value</td></tr><tr><td>N = 357</td><td>%</td><td>N = 1,428</td><td>%</td></tr><tr><td>Age at DM</td><td colspan="4"> </td><td>0.483</td></tr><tr><td>30-60</td><td>69</td><td>15.90</td><td>300</td><td>17.28<... | <table><tr><td rowspan="2">Variables</td><td colspan="2">Cases</td><td colspan="2">Controls</td><td rowspan="2">P value</td></tr><tr><td>N = 357</td><td>%</td><td>N = 1,428</td><td>%</td></tr><tr><td>Age at DM</td><td colspan="4"></td><td>0.483</td></tr><tr><td>30-60</td><td>69</td><td>15.90</td><td>300</td><td>17.28</... | <table><tr><td rowspan="2">Variables</td><td colspan="2">Cases</td><td colspan="2">Controls</td><td rowspan="2">P value</td></tr><tr><td>N = 357</td><td>%</td><td>N = 1,428</td><td>%</td></tr><tr><td>Meglitinides (Glinides)</td><td>35</td><td>8.06</td><td>241</td><td>13.88</td><td><0.001</td></tr><tr><td>DPP-4 inhibito... |
a3af96cadc1036c5101ee8a450aefd142a40593c93ffc0a8d7a54aa32af807d8.png | complex | <table><tr><td>Gram</td><td>Bacterial strain</td><td colspan="5">Concentration of SS-capped AgNPs (mM)</td><td>MIC (mM)</td></tr><tr><td> </td><td> </td><td>0.001</td><td>0.004</td><td>0.008</td><td>0.017</td><td>0.034</td><td> </td></tr><tr><td>+</td><td>MRSA</td><td>T</td><td>T/C</td><td>C</td><td>C</td><td>C</td><td... | <table><tr><td>Gram</td><td>Bacterial strain</td><td colspan="5">Concentration of SS-capped AgNPs (mM)</td><td>MIC (mM)</td></tr></table> | <table><tr><td></td><td></td><td>0.001</td><td>0.004</td><td>0.008</td><td>0.017</td><td>0.034</td><td></td></tr><tr><td>+</td><td>MRSA</td><td>T</td><td>T/C</td><td>C</td><td>C</td><td>C</td><td>0.008</td></tr><tr><td>+</td><td>S. aureus</td><td>T</td><td>T/C</td><td>C</td><td>C</td><td>C</td><td>0.008</td></tr><tr><t... |
776e7ec3a076a5406fe18663991eb3a94ab5c591da9b2aa0ff67c909b2ee9c10.png | complex | <table><tr><td>ACE genotype</td><td colspan="2">II</td><td colspan="2">D carriers</td></tr><tr><td>Percent body fat category</td><td>Normal fat(n = 30)</td><td>Overfat(n = 15)</td><td>Normal fat(n = 62)</td><td>Overfat(n = 45)</td></tr><tr><td>SBP (mmHg)</td><td>103.2 (1.3)*</td><td>105.7 (1.9)</td><td>102.6 (0.9)#</td... | <table><tr><td>ACE genotype</td><td>II</td></tr><tr><td>Percent body fat category</td><td>Normal fat(n = 30)</td></tr><tr><td>SBP (mmHg)</td><td>103.2 (1.3)*</td></tr><tr><td>DBP (mmHg)</td><td>68.6 (1.1)</td></tr></table> | <table><tr><td>II</td><td colspan="2">D carriers</td></tr><tr><td>Overfat(n = 15)</td><td>Normal fat(n = 62)</td><td>Overfat(n = 45)</td></tr><tr><td>105.7 (1.9)</td><td>102.6 (0.9)#</td><td>108.1 (1.1)*#</td></tr><tr><td>70.2 (1.6)</td><td>69.5 (0.8)</td><td>71.4 (1.0)</td></tr></table> |
9b854aff9d81ee45dcb53625cab4c511db5ff782adb1ae0f964ad460dccafa15.png | complex | <table><tr><td></td><td>TCPC (n = 6)</td><td>TCPC + AVR (n = 4)</td></tr><tr><td colspan="3">Morphology of AV valve</td></tr><tr><td> SAVV (morphologically tricuspid valve)</td><td>5 (83 %)</td><td>0</td></tr><tr><td> CAAV</td><td>1 (17 %) early death</td><td>4 (100 %)</td></tr><tr><td colspan="3">Degree of AV valve re... | <table><tr><td></td><td>TCPC (n = 6)</td></tr><tr><td colspan="2">Morphology of AV valve</td></tr><tr><td>SAVV (morphologically tricuspid valve)</td><td>5 (83 %)</td></tr><tr><td>CAAV</td><td>1 (17 %) early death</td></tr><tr><td colspan="2">Degree of AV valve regurgitation</td></tr><tr><td>Slight</td><td>3 (50 %)</td>... | <table><tr><td>TCPC + AVR (n = 4)</td></tr><tr><td>Morphology of AV valve</td></tr><tr><td>0</td></tr><tr><td>4 (100 %)</td></tr><tr><td>Degree of AV valve regurgitation</td></tr><tr><td>0</td></tr><tr><td>0</td></tr><tr><td>2 (50 %)</td></tr><tr><td>2 (50 %)</td></tr><tr><td>0</td></tr></table> |
2481b02a8aef0eae67a907b2dbd10e9689beefc7d35c161f62a1c6e859d7d951.png | simple | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Age at onset (y)</td><td>6</td><td>1</td><td>0.8</td><td>2</td></tr><tr><td>Age at diagnosis* (y)</td><td>10</td><td>6</td><td>11</td><td>5</td></tr><tr><td>Present age (y)</td><td>13</td><td>8</td><td>15</td><td>Died at 8 Y</td></tr><tr><t... | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Age at onset (y)</td><td>6</td><td>1</td><td>0.8</td><td>2</td></tr><tr><td>Age at diagnosis* (y)</td><td>10</td><td>6</td><td>11</td><td>5</td></tr><tr><td>Present age (y)</td><td>13</td><td>8</td><td>15</td><td>Died at 8 Y</td></tr><tr><t... | <table><tr><td>Patient</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Tonsils</td><td>t</td><td>poplastic</td><td>bsent</td><td>ypoplastic</td></tr><tr><td>Duration of IVIG treatment (m)</td><td>25</td><td>17</td><td>33</td><td>12</td></tr></table> |
675d2091e54e8c98bed94062018d9e4ac5f153254633539bf93195f05905c4a5.png | simple | <table><tr><td>Gene Set</td><td>Number of Genes</td><td>Categorized Genes</td><td><i>p</i>-Value</td></tr><tr><td>Galactose metabolism</td><td>16</td><td>Gck</td><td><0.0001</td></tr><tr><td>Cysteine metabolism</td><td>16</td><td>Sult1c2</td><td>0.003</td></tr><tr><td>Aminoacyl-tRNA biosynthesis</td><td>16</td><td>V... | <table><tr><td>Gene Set</td><td>Number of Genes</td><td>Categorized Genes</td><td>p-Value</td></tr><tr><td>Galactose metabolism</td><td>16</td><td>Gck</td><td><0.0001</td></tr><tr><td>Cysteine metabolism</td><td>16</td><td>Sult1c2</td><td>0.003</td></tr><tr><td>Aminoacyl-tRNA biosynthesis</td><td>16</td><td>Vars2</td><... | <table><tr><td>Chondroitin sulfate biosynthesis</td><td>14</td><td>B3gat2Chst12</td><td>0.1260</td></tr><tr><td>Antigen processing and presentation</td><td>58</td><td>RT1-Aw2</td><td>0.163</td></tr></table> |
4cf7fe0232d3be583721f6bf38b3ef4b1db3479a431c367cfa4a1b10b5511c83.png | simple | <table><tr><td>Primer</td><td>Forward</td><td>Reverse</td></tr><tr><td>IFN-γ</td><td>GGTCAACAACCCACAGGTCC</td><td>CGACTCCTTTTCCGCTTCC</td></tr><tr><td>IL-4</td><td>TCTCGAATGTACCAGGAGCCATATC</td><td>AGCACCTTGGAAGCCCTACAGA</td></tr><tr><td>IL-10</td><td>GCTCCTAGAGCTGCGGACT</td><td>TGTTGTCCAGCTGGTCCTTT</td></tr><tr><... | <table><tr><td>Primer</td><td>Forward</td><td>Reverse</td></tr><tr><td>IFN-γ</td><td>GGTCAACAACCCACAGGTCC</td><td>CGACTCCTTTTCCGCTTCC</td></tr><tr><td>IL-4</td><td>TCTCGAATGTACCAGGAGCCATATC</td><td>AGCACCTTGGAAGCCCTACAGA</td></tr><tr><td>IL-10</td><td>GCTCCTAGAGCTGCGGACT</td><td>TGTTGTCCAGCTGGTCCTTT</td></tr><tr><td>IL... | <table><tr><td>Primer</td><td>Forward</td><td>Reverse</td></tr><tr><td>GAPDH</td><td>CAACTTTGGCATTGTGGAAGG</td><td>ACACATTGGGGGTAGGAACAC</td></tr></table> |
7f0a137f90e8c490a9ae37b7f08fb8e43d42235484bf1d36d3053427c2b99d84.png | simple | <table><tr><td>Aspects</td><td>Score/question</td></tr><tr><td>1. Risk factors associated with obstetric fistula</td><td>1</td></tr><tr><td> - Early pregnancy</td><td>0.125</td></tr><tr><td> - Home delivery</td><td>0.125</td></tr><tr><td> - Female Genital Mutilation</td><td>0.125</td></tr><tr><td> - Evil spirits</td><t... | <table><tr><td>Aspects</td><td>Score/question</td></tr><tr><td>1. Risk factors associated with obstetric fistula</td><td>1</td></tr><tr><td>- Early pregnancy</td><td>0.125</td></tr><tr><td>- Home delivery</td><td>0.125</td></tr><tr><td>- Female Genital Mutilation</td><td>0.125</td></tr><tr><td>- Evil spirits</td><td>0.... | <table><tr><td>2. Symptoms of obstetric fistula</td><td>1</td></tr><tr><td>- Urinary incontinence</td><td>0.2</td></tr><tr><td>- Faecal incontinence</td><td>0.2</td></tr><tr><td>- Continuous sleeping</td><td>0.2</td></tr><tr><td>- Stomach ache</td><td>0.2</td></tr><tr><td>- Vulva irritation</td><td>0.2</td></tr><tr><td... |
a712e534ee76d10a4bda9a440eb79816f343ef7240635a76838ee3557ab33569.png | simple | <table><tr><td>Standard Deviation (change)</td><td>Treatment Change</td><td>N per group</td><td>N total</td></tr><tr><td>18</td><td>20</td><td>14</td><td>28</td></tr><tr><td></td><td>28</td><td>8</td><td>16</td></tr><tr><td></td><td>30</td><td>7</td><td>14</td></tr><tr><td>20</td><td>20</td><td>17</td><td>34</td></tr><... | <table><tr><td>Standard Deviation (change)</td><td>Treatment Change</td><td>N per group</td><td>N total</td></tr><tr><td>18</td><td>20</td><td>14</td><td>28</td></tr></table> | <table><tr><td></td><td>28</td><td>8</td><td>16</td></tr><tr><td></td><td>30</td><td>7</td><td>14</td></tr><tr><td>20</td><td>20</td><td>17</td><td>34</td></tr><tr><td></td><td>28</td><td>9</td><td>18</td></tr><tr><td></td><td>30</td><td>8</td><td>16</td></tr><tr><td>22</td><td>20</td><td>20</td><td>40</td></tr><tr><td... |
7921fa15f991ea7d8b11237280dd485db9764a7b9c6d18a0a2f255b1dd3db29a.png | complex | <table><tr><td rowspan="2" colspan="2"><i>Patients’ characteristics</i></td><td>ADC</td><td>NAET</td><td>Whole sample</td><td rowspan="2">Chi square (<i>p</i>-value)</td></tr><tr><td>Number (%)</td><td>Number (%)</td><td>Number (%)</td></tr><tr><td rowspan="3"><i>Industrial sector</i></td><td><i>Wood</i></td><td>... | <table><tr><td rowspan="2">Patients’ characteristics</td></tr><tr></tr><tr><td rowspan="3">Industrial sector</td></tr><tr></tr><tr></tr><tr><td rowspan="3">Age (years)</td></tr><tr></tr><tr></tr><tr><td rowspan="3">Smoking (pack-years)</td></tr><tr></tr><tr></tr><tr><td rowspan="2">Sex</td></tr><tr></tr><tr><td rowspan... | <table><tr><td rowspan="2">Patients’ characteristics</td><td>ADC</td><td>NAET</td><td>Whole sample</td><td rowspan="2">Chi square (p-value)</td></tr><tr><td>Number (%)</td><td>Number (%)</td><td>Number (%)</td></tr><tr><td>Wood</td><td>16 (50)</td><td>5 (24)</td><td>21 (40)</td><td rowspan="3">14.60 (0.001)</td></tr><t... |
e06c362d47ab1fc02d0e12eb06e7b847e80985fc5883a1744c083e4faf271d4a.png | simple | <table><tr><td></td><td>sense</td><td>antisense</td></tr><tr><td>#1</td><td>GTATCTGCACTCTCAATCAGGAGC</td><td>AAACTGTAACCCCTATCTCTACTCAC</td></tr><tr><td>#2</td><td>CCTGGGTTTCCACCATATGCTTTC</td><td>AGTTCCTTGCACTCCTGTTAACAA</td></tr><tr><td>#3</td><td>CCTGGGTTTCCACCATATGCTTTC</td><td>GGTCGCCTAGTGTCATGACCA</td></tr><tr><t... | <table><tr><td></td><td>sense</td><td>antisense</td></tr><tr><td>#1</td><td>GTATCTGCACTCTCAATCAGGAGC</td><td>AAACTGTAACCCCTATCTCTACTCAC</td></tr><tr><td>#2</td><td>CCTGGGTTTCCACCATATGCTTTC</td><td>AGTTCCTTGCACTCCTGTTAACAA</td></tr><tr><td>#3</td><td>CCTGGGTTTCCACCAT</td><td>GGTCG</td></tr></table> | <table><tr><td></td><td>ATGCTTTC</td><td>CCTAGTGTCATGACCA</td></tr><tr><td>#4</td><td>GACCACATCCCAACCGAATC</td><td>CACAGGCCAGACTGACACCC</td></tr><tr><td>#5</td><td>GACCACATCCCAACCGAATC</td><td>CTGACACCCAGTAGTGAAGG</td></tr><tr><td>#6</td><td>GATAGCAGCCGCAGAAGAGC</td><td>CCACCTGGGTTTCCACCATA</td></tr></table> |
68c3f597e94cfde36aeced7a7412f0e72ec19bc4df5404124667f18ffd0c8b5b.png | simple | <table><tr><td>Commercial laboratory variable</td><td>Mean change younger cohort</td><td>Mean change older cohort</td><td>p-value</td></tr><tr><td>CD3%</td><td>−2.75</td><td>2.33</td><td>0.036</td></tr><tr><td>CD4%</td><td>−2.50</td><td>1.67</td><td>0.028</td></tr><tr><td>WBC</td><td>2.13</td><td>−0.7... | <table><tr><td>Commercial laboratory variable</td><td>Mean change younger cohort</td><td>Mean change older cohort</td><td>p-value</td></tr></table> | <table><tr><td>CD3%</td><td>−2.75</td><td>2.33</td><td>0.036</td></tr><tr><td>CD4%</td><td>−2.50</td><td>1.67</td><td>0.028</td></tr><tr><td>WBC</td><td>2.13</td><td>−0.70</td><td>0.031</td></tr><tr><td>IgA</td><td>4.25</td><td>−13.17</td><td>0.059</td></tr><tr><td>Zinc/Copper Ratio</td><td>−0.08</td><td>0.13</td><td>0... |
fbc64a7c9f2bff4414f3218e926e0259df79e3911762d5caef8b03b434c1c674.png | simple | <table><tr><td>Strain</td><td>Source</td><td>Accession no.</td><td>Genome size (bp)</td><td><i>N</i><sub>50</sub> (bp)</td><td>No. of scaffolds (>300 bp)</td><td>G+C content (%)</td></tr><tr><td><i>Arcobacter</i> sp. AF1028</td><td>Human feces</td><td>JART00000000</td><td>2,414,790</td><td>148,259</td><td>46</td><td... | <table><tr><td>Strain</td><td>Source</td><td>Accession no.</td><td>Genome size (bp)</td><td>N50 (bp)</td><td>No. of scaffolds (>300 bp)</td><td>G+C content (%)</td></tr><tr><td>Arcobacter sp. AF1028</td><td>Human feces</td><td>JART00000000</td><td>2,414,790</td><td>148,259</td><td>46</td><td>27.24</td></tr></table> | <table><tr><td>Strain</td><td>Source</td><td>Accession no.</td><td>Genome size (bp)</td><td>N50 (bp)</td><td>No. of scaffolds (>300 bp)</td><td>G+C content (%)</td></tr><tr><td>Arcobacter sp. AF1078</td><td>Human feces</td><td>JARS00000000</td><td>2,496,885</td><td>127,252</td><td>53</td><td>27.18</td></tr></table> |
1dc0ec8422e38e342fc512fa1b1107801017099a55faafe06e17e70fa585662f.png | complex | <table><tr><td></td><td>All articles (n=168)</td><td>Including <i>NEJM</i> protocols (n=61)</td></tr><tr><td>Characteristics</td><td>n (%)</td><td>n (%)</td></tr><tr><td colspan="3">Journal</td></tr><tr><td> <i>NEJM</i></td><td>61 (36)</td><td>61</td></tr><tr><td> <i>Lancet</i></td><td>64 (38)</td><td></td></tr><tr><td... | <table><tr><td></td><td>All articles (n=168)</td></tr><tr><td>Characteristics</td><td>n (%)</td></tr><tr><td colspan="2">Journal</td></tr><tr><td>NEJM</td><td>61 (36)</td></tr><tr><td>Lancet</td><td>64 (38)</td></tr><tr><td>JAMA</td><td>19 (11)</td></tr><tr><td>BMJ</td><td>8 (5)</td></tr><tr><td>Annals of Internal Medi... | <table><tr><td>Including NEJM protocols (n=61)</td></tr><tr><td>n (%)</td></tr><tr><td>Journal</td></tr><tr><td>61</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>Year of publication</td></tr><tr><td>9 (15)</td></tr><tr><td>9... |
2e9cdfa979466c8a94ff33a0e25b96d96c0bf7f1d0f051cbac8fa3c7c2a9df4d.png | simple | <table><tr><td>Author</td><td>Study design</td><td>Oral health criteria</td><td>Study population</td><td>Results</td></tr><tr><td>Bundgaard et al. (85)</td><td>Case-control</td><td>Missing teeth</td><td>161 patients and 400 controls (Denmark)</td><td>Significantly increased risk of developing oral SCCA for patients wit... | <table><tr><td>Author</td><td>Study design</td><td>Oral health criteria</td><td>Study population</td><td>Results</td></tr><tr><td>Bundgaard et al. (85)</td><td>Case-control</td><td>Missing teeth</td><td>161 patients and 400 controls (Denmark)</td><td>Significantly increased risk of developing oral SCCA for patients wit... | <table><tr><td>Author</td><td>Study design</td><td>Oral health criteria</td><td>Study population</td><td>Results</td></tr><tr><td>l. (92)</td><td>t</td><td>l attachment loss (CAL)</td><td>ancerous lesions (United States)</td><td>clinical attachment loss</td></tr><tr><td>Tezal et al. (81)</td><td>Case-control</td><td>Al... |
767d51dd80a1c15d4605fa6ab857d4e548ca4591a62e543408dc10094c498e97.png | simple | <table><tr><td>Injure</td><td>1-4 y</td><td>5-9 y</td><td>10-14 y</td></tr><tr><td>Transport accidents</td><td>21(47.7)</td><td>23(39.7)</td><td>45(51.7)</td></tr><tr><td>Accidental drowning and submersion</td><td>2(4.5)</td><td>17(29.3)</td><td>28(32.2)</td></tr><tr><td>Falls</td><td>7(15.9)</td><td>5(8.6)</td><td>5(5... | <table><tr><td>Injure</td><td>1-4 y</td><td>5-9 y</td><td>10-14 y</td></tr><tr><td>Transport accidents</td><td>21(47.7)</td><td>23(39.7)</td><td>45(51.7)</td></tr><tr><td>Accidental drowning and submersion</td><td>2(4.5)</td><td>17(29.3)</td><td>28(32.2)</td></tr></table> | <table><tr><td>Falls</td><td>7(15.9)</td><td>5(8.6)</td><td>5(5.7)</td></tr><tr><td>Suicide</td><td>0(0)</td><td>1(1.7)</td><td>4(4.6)</td></tr><tr><td>Suffocation</td><td>4(9.0)</td><td>3(5.2)</td><td>2(2.3)</td></tr><tr><td>Other</td><td>14(31.8)</td><td>11(19)</td><td>3(3.4)</td></tr></table> |
e969908397908803b6ec9a75912b2e67fa66276893b274cbec4bd8e646510c50.png | simple | <table><tr><td>Characteristic</td><td>Patients (n= 19)(%)</td></tr><tr><td>Sex (males/females)</td><td>12/7</td></tr><tr><td>Age, years, median (range)</td><td>54 (30–75)</td></tr><tr><td>Underlying liver disease</td><td> </td></tr><tr><td>Hepatitis B virus</td><td>11 (57.89)</td></tr><tr><td>Alcoholic</td><td>3 ... | <table><tr><td>Characteristic</td><td>Patients (n= 19)(%)</td></tr><tr><td>Sex (males/females)</td><td>12/7</td></tr><tr><td>Age, years, median (range)</td><td>54 (30–75)</td></tr><tr><td>Underlying liver disease</td><td></td></tr><tr><td>Hepatitis B virus</td><td>11 (57.89)</td></tr><tr><td>Alcoholic</td><td>3 (15.79)... | <table><tr><td>Characteristic</td><td>Patients (n= 19)(%)</td></tr><tr><td>Child B</td><td>6 (31.58)</td></tr><tr><td>Child C</td><td>13 (68.42)</td></tr><tr><td>MELD (mean ± SD)</td><td>22 ± 7</td></tr><tr><td>Neutropenia</td><td>2 (10.53)</td></tr><tr><td>Broad-spectrum antibiotics usage</td><td>18 (94.74)</td></tr><... |
b52fd66d697a58595277f3390f9e6c1fad26e4b8ad0d1de266ae8f1001afcd88.png | complex | <table><tr><td></td><td>Mean</td><td>Median</td><td>Min</td><td>Max</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 1st Year Following Approval</td></tr><tr><td>Bare metal stent patients</td><td>42.8%</td><td>30.0%</td><td>5.1%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>16.8%</td><td>10.0%... | <table><tr><td></td><td>Mean</td><td>Median</td><td>Min</td><td>Max</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 1st Year Following Approval</td></tr><tr><td>Bare metal stent patients</td><td>42.8%</td><td>30.0%</td><td>5.1%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>16.8%</td><td>10.0%... | <table><tr><td colspan="5">proval</td></tr><tr><td>Bare metal stent patients</td><td>56.0%</td><td>50.0%</td><td>10.2%</td><td>100.0%</td></tr><tr><td>CABG patients</td><td>25.5%</td><td>20.0%</td><td>5.0%</td><td>80.0%</td></tr><tr><td colspan="5">% of Patients Who Should Receive DES, 3rd Year Following Approval</td><... |
c9a08fda830b3880a99294e628853f07f53769feb818b3fc7d38c9038f9c07bb.png | complex | <table><tr><td rowspan="3">Job satisfaction domains</td><td colspan="2">Level of satisfaction</td></tr><tr><td>Satisfied</td><td>Dissatisfied</td></tr><tr><td>N (%)</td><td>N (%)</td></tr><tr><td>Leadership and planning</td><td>175 (43.2)</td><td>230 (56.8)</td></tr><tr><td>Culture and communications</td><td>180 (44.6)... | <table><tr><td rowspan="3">Job satisfaction domains</td><td colspan="2">Level of satisfaction</td></tr><tr><td>Satisfied</td><td>Dissatisfied</td></tr><tr><td>N (%)</td><td>N (%)</td></tr><tr><td>Leadership and planning</td><td>175 (43.2)</td><td>230 (56.8)</td></tr><tr><td>Culture and communications</td><td>180 (44.6)... | <table><tr><td>Training and development</td><td>165 (41.4)</td><td>237 (58.6)</td></tr><tr><td>Pay and benefits</td><td>148 (36.5)</td><td>257 (63.5)</td></tr><tr><td>Coworker relation ship</td><td>209 (51.6)</td><td>196 (48.4)</td></tr><tr><td>Overall satisfaction</td><td>179 (44.2)</td><td>226 (55.8)</td></tr></table... |
af658c110b7145ee1b0b49c8aa859214fda0dc1cad278331bc63f1d34baf5c3a.png | simple | <table><tr><td></td><td>Overweight*</td><td>Body fat (%)<sup>+</sup></td><td>Lean body mass (kg)<sup>+</sup></td></tr><tr><td>Birth weight (z)</td><td>1.18 (1.02 to 1.35)</td><td>0.02 (−0.39 to 0.43)</td><td>1.54 (1.15 to 1.93)</td></tr><tr><td> <i>P </i>for trend</td><td>0.02</td><td>0.9</td><td><0.001</td></... | <table><tr><td></td><td>Overweight*</td><td>Body fat (%)+</td><td>Lean body mass (kg)+</td></tr><tr><td>Birth weight (z)</td><td>1.18 (1.02 to 1.35)</td><td>0.02 (−0.39 to 0.43)</td><td>1.54 (1.15 to 1.93)</td></tr><tr><td>P for trend</td><td>0.02</td><td>0.9</td><td><0.001</td></tr><tr><td>Ponderal index (z)</td><td>1... | <table><tr><td></td><td>Overweight*</td><td>Body fat (%)+</td><td>Lean body mass (kg)+</td></tr><tr><td>Birth weight (z)</td><td>1.11 (0.94 to 1.31)</td><td>0.21 (−0.29 to 0.71)</td><td>1.46 (0.95 to 1.97)</td></tr><tr><td>P for trend</td><td>0.2</td><td>0.4</td><td><0.001</td></tr><tr><td>Ponderal index (z)</td><td>1.... |
c42739bf0afc4d7a89a7176c422d00464d6003d2edd1363612aa2d20ffbc9901.png | complex | <table><tr><td>Surgical Margins</td><td colspan="3">Pathological Stage</td><td>P</td></tr><tr><td>(Group 1)</td><td>pT2</td><td>pT3</td><td>Total</td><td></td></tr><tr><td>Negative</td><td>44 (95.7%)</td><td>02 (4.3%)</td><td>46 (100%)</td><td>0.027<sub>F</sub></td></tr><tr><td>Positive</td><td>06 (66.7%)</td><td>03 (3... | <table><tr><td>Surgical Margins</td><td colspan="3">Pathological Stage</td><td>P</td></tr><tr><td>(Group 1)</td><td>pT2</td><td>pT3</td><td>Total</td><td></td></tr><tr><td>Negative</td><td>44 (95.7%)</td><td>02 (4.3%)</td><td>46 (100%)</td><td>0.027F</td></tr><tr><td>Positive</td><td>06 (66.7%)</td><td>03 (33.3%)</td><... | <table><tr><td>Surgical Margins</td><td colspan="3">Pathological Stage</td><td>P</td></tr><tr><td>(Group 2)</td><td>pT2</td><td>T3</td><td></td><td></td></tr><tr><td>Negative</td><td>44 (95.7%)</td><td>02 (4.3%)</td><td>46 (100%)</td><td><0.001F</td></tr><tr><td>Positive</td><td>02 (20.0%)</td><td>08 (80.0%)</td><td>10... |
16a0c73f1137f362bdafc6287065dac32074d6736b00208db5f3caf61b1bc603.png | complex | <table><tr><td rowspan="2">Activity and Level</td><td rowspan="2">No.</td><td colspan="2">Model 1<sup>a</sup></td><td colspan="2">Model 2<sup>b</sup></td><td colspan="2">Model 3<sup>c</sup></td></tr><tr><td>B</td><td>95% CI</td><td>B</td><td>95% CI</td><td>B</td><td>95% CI</td></tr><tr><td>Attendance at sports/PA clubs... | <table><tr><td rowspan="2">Activity and Level</td><td rowspan="2">No.</td><td colspan="2">Model 1a</td></tr><tr><td>B</td><td>95% CI</td></tr><tr><td>Attendance at sports/PA clubs</td><td></td><td></td><td></td></tr><tr><td>Low</td><td>2,333</td><td>0</td><td>Referent</td></tr><tr><td>Medium</td><td>2,299</td><td>2.0</... | <table><tr><td colspan="2">Model 2b</td><td colspan="2">Model 3c</td></tr><tr><td>B</td><td>95% CI</td><td>B</td><td>95% CI</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>0</td><td>Referent</td><td>0</td><td>Referent</td></tr><tr><td>0.6</td><td>0.1, 1.1</td><td>0.3</td><td>−0.2, 0.8</td></tr><tr><td>1.2... |
4a25ed4904dd1766f4ab575126f658bd3613b04e41b671fe6e1daadc7ef0f29b.png | complex | <table><tr><td rowspan="2">Cy-3-G (μmol/L)</td><td colspan="2">P<sub>app</sub> (×10<sup>−7</sup> cm/s)</td><td rowspan="2">Efflux Ratio</td><td rowspan="2">Transport Efficiency (%)</td></tr><tr><td>B → A</td><td>A → B</td></tr><tr><td>10</td><td>10.57 ± 1.12</td><td>14.96 ± 1.88</t... | <table><tr><td rowspan="2">Cy-3-G (μmol/L)</td><td colspan="2">Papp (×10−7 cm/s)</td><td rowspan="2">Efflux Ratio</td><td rowspan="2">Transport Efficiency (%)</td></tr><tr><td>B → A</td><td>A → B</td></tr></table> | <table><tr><td>10</td><td>10.57 ± 1.12</td><td>14.96 ± 1.88</td><td>0.71</td><td>2.41</td></tr><tr><td>20</td><td>6.45 ± 0.46</td><td>8.98 ± 1.12</td><td>0.72</td><td>1.45</td></tr><tr><td>40</td><td>3.58 ± 0.37</td><td>4.75 ± 0.51</td><td>0.75</td><td>0.76</td></tr></table> |
8b140c2d3ea53e7ac559d2d4f0b763e8cc0d68c178a76760db6f7335bc34acf9.png | simple | <table><tr><td>Variable</td><td>Neonatal mortality rate (NMR)</td><td>Infant mortality rate (IMR)</td><td>Under-5 mortality rate (U5MR)</td></tr><tr><td>Behvarz density</td><td>-0.108 (-2.09 – 1.87)</td><td>-0.021 (-0.13 – 0.08)</td><td>-0.012 (-0.11 – 0.09)</td></tr><tr><td>Effect of rural family phy... | <table><tr><td>Variable</td><td>Neonatal mortality rate (NMR)</td><td>Infant mortality rate (IMR)</td><td>Under-5 mortality rate (U5MR)</td></tr><tr><td>Behvarz density</td><td>-0.108 (-2.09 – 1.87)</td><td>-0.021 (-0.13 – 0.08)</td><td>-0.012 (-0.11 – 0.09)</td></tr><tr><td>Effect of rural family physician program and... | <table><tr><td>Logarithmic scale of rural population size</td><td>-0.918 (-4.05 – 2.21)</td><td>-0.223* (-0.39 – 0.06)</td><td>-0.219* (-0.38 – -0.06)</td></tr></table> |
295bbd109e7d96cf15e0b6302128512d3b7d74926138dde7682dba46e8f9a4f5.png | simple | <table><tr><td>Outcomes</td><td>Support (N = 105)</td><td>Control (N = 107)</td><td>RR (95%CI)</td><td>p value</td></tr><tr><td>Apgar score at 1 minute < 7</td><td>20</td><td>21</td><td>0.97 (0.56–1.68)</td><td>0.915</td></tr><tr><td>Apgar score at 5 minutes < 7</td><td>3</td><td>2</td><td>1.53 (0.26–... | <table><tr><td>Outcomes</td></tr><tr><td>Apgar score at 1 minute < 7</td></tr><tr><td>Apgar score at 5 minutes < 7</td></tr><tr><td>Birthweight (g) (mean ± SD 95%)</td></tr><tr><td>Admission to NICU</td></tr><tr><td>Immediate contact mother/newborn</td></tr><tr><td>Time of contact mother/newborn (min) (mean ± 95% SD)</... | <table><tr><td>Support (N = 105)</td><td>Control (N = 107)</td><td>RR (95%CI)</td><td>p value</td></tr><tr><td>20</td><td>21</td><td>0.97 (0.56–1.68)</td><td>0.915</td></tr><tr><td>3</td><td>2</td><td>1.53 (0.26–8.96)</td><td>0.681*</td></tr><tr><td>3.197 (2.360–4.245)</td><td>3.246 (2.410–4.145)</td><td>-</td><td>0.37... |
6b35df04f345cf45302e0129bd3bee1e8fb359a3e00f2b3508c59fc1d4b49af6.png | simple | <table><tr><td>Method</td><td>Precision (%)</td><td>Recall (%)</td><td>F-score (%)</td></tr><tr><td>hHMM</td><td>98.5 ± 0.4</td><td>93.5 ± 1.9</td><td>95.9 ± 0.9</td></tr><tr><td>eDTW</td><td>94 ± 1.2</td><td>93.5 ± 0.8</td><td>93.8 ± 0.5</td></tr><tr><td>Peak detection</td><td>87.4 ±... | <table><tr><td>Method</td><td>Precision (%)</td><td>Recall (%)</td><td>F-score (%)</td></tr><tr><td>hHMM</td><td>98.5 ± 0.4</td><td>93.5 ± 1.9</td><td>95.9 ± 0.9</td></tr></table> | <table><tr><td>Method</td><td>Precision (%)</td><td>Recall (%)</td><td>F-score (%)</td></tr><tr><td>eDTW</td><td>94 ± 1.2</td><td>93.5 ± 0.8</td><td>93.8 ± 0.5</td></tr><tr><td>Peak detection</td><td>87.4 ± 1.2</td><td>95.9 ± 1.8</td><td>91.5 ± 0.4</td></tr><tr><td>pDTW</td><td>91.8 ± 2.1</td><td>90.1 ± 2.2</td><td>90.... |
23bf7f5fc7a6ef2ed3478e88a65f92b74bbda798ef82dd145015a2544c73d134.png | simple | <table><tr><td>UNIPROT KEY</td><td>DESCRIPTION</td><td>MW (kDa)</td><td>Mascot score</td><td>A/C ratio</td><td>A/C std. dev. </td><td>A/C <i>p</i> value</td><td>At/C ratio</td><td>At/C std. dev.</td><td>At/C <i>p</i> value</td></tr><tr><td>Q9JI91</td><td>Alpha-actinin-2</td><td>103.8</td><td>353.78</td><td>2.875</td><t... | <table><tr><td>UNIPROT KEY</td><td>DESCRIPTION</td><td>MW (kDa)</td><td>Mascot score</td><td>A/C ratio</td><td>A/C std. dev.</td><td>A/C p value</td><td>At/C ratio</td><td>At/C std. dev.</td><td>At/C p value</td></tr><tr><td>Q9JI91</td><td>Alpha-actinin-2</td><td>103.8</td><td>353.78</td><td>2.875</td><td>0.825</td><td... | <table><tr><td>UNIPROT KEY</td><td>DESCRIPTION</td><td>MW (kDa)</td><td>Mascot score</td><td>A/C ratio</td><td>A/C std. dev.</td><td>A/C p value</td><td>At/C ratio</td><td>At/C std. dev.</td><td>At/C p value</td></tr><tr><td>P26043</td><td>Radixin</td><td>68.5</td><td>691.5</td><td>0.871</td><td>0.106</td><td>3.00E-01<... |
0b49c7b6a19457bc5dbbd21ac8bda1cda7aead91205b80845b6b6c8308659769.png | simple | <table><tr><td> Variables</td><td> Persistently Active (n=45)</td><td> Persistently Sedentary (n=10)</td><td><i>p-</i>value</td></tr><tr><td></td><td> Median (IR)</td><td> Median (IR)</td><td></td></tr><tr><td> M/F</td><td>29 / 16</td><td>4 / 6</td><td></td></tr><tr><td> Age (years)</td><td>38.3 (6.9)</td><td>43.8 (13)... | <table><tr><td>Variables</td><td>Persistently Active (n=45)</td><td>Persistently Sedentary (n=10)</td><td>p-value</td></tr><tr><td></td><td>Median (IR)</td><td>Median (IR)</td><td></td></tr><tr><td>M/F</td><td>29 / 16</td><td>4 / 6</td><td></td></tr><tr><td>Age (years)</td><td>38.3 (6.9)</td><td>43.8 (13)</td><td>0.121... | <table><tr><td>LDL-C/HDL-C (mg/dL)</td><td>2.3 (1.2)</td><td>2.7 (1.3)</td><td>0.789</td></tr><tr><td>VLDL-C (mg/dL)</td><td>15.2 (9.3)</td><td>25.5 (7.4)</td><td>0.001</td></tr><tr><td>HbA1c (mmol/mol)</td><td>5.3 (0.5)</td><td>5.3 (0.8)</td><td>0.637</td></tr><tr><td>CIT (mm)</td><td>0.60 (0.11)</td><td>0.78 (0.11)</... |
e1699bebb2144df18c7ba21a3eac3d4ae035c5cb524cc50599ae8694826d9baf.png | simple | <table><tr><td>Risk factor</td><td>Intervention options if risk factor identified</td></tr><tr><td>History of falls/falls injuries</td><td>Referral to GPAppropriate acute management if injury recent</td></tr><tr><td>Medications (number)</td><td>Refer to GP for medication review</td></tr><tr><td>Medications (associated ... | <table><tr><td>Risk factor</td></tr><tr><td>History of falls/falls injuries</td></tr><tr><td>Medications (number)</td></tr><tr><td>Medications (associated with increased falls risk)</td></tr><tr><td>Medical conditions (associated with increased falls risk)</td></tr><tr><td>Sensory loss: vision</td></tr><tr><td>Sensory ... | <table><tr><td>Intervention options if risk factor identified</td></tr><tr><td>Referral to GPAppropriate acute management if injury recent</td></tr><tr><td>Refer to GP for medication review</td></tr><tr><td>Refer to GP/specialist for medication review</td></tr><tr><td>Refer to GP/specialist for review</td></tr><tr><td>... |
b7ff5d4719cfefa710119170ffc6eee5af57e171ccf8780895891cccfe7bc879.png | simple | <table><tr><td>Patient #</td><td>Sex</td><td>Age(year)</td><td>Injected activity (MBq)</td><td>Diagnosis</td></tr><tr><td>1</td><td>M</td><td>2</td><td>320</td><td>Mediastinum 7-cm diameter NET</td></tr><tr><td>2</td><td>F</td><td>7</td><td>450</td><td></td></tr><tr><td>3</td><td>M</td><td>11</td><td>490</td><td>Right ... | <table><tr><td>Patient #</td><td>Sex</td><td>Age(year)</td><td>Injected activity (MBq)</td><td>Diagnosis</td></tr><tr><td>1</td><td>M</td><td>2</td><td>320</td><td>Mediastinum 7-cm diameter NET</td></tr><tr><td>2</td><td>F</td><td>7</td><td>450</td><td></td></tr><tr><td>3</td><td>M</td><td>11</td><td>490</td><td>Right ... | <table><tr><td>Patient #</td><td>Sex</td><td>Age(year)</td><td>Injected activity (MBq)</td><td>Diagnosis</td></tr><tr><td>6</td><td>F</td><td>13</td><td>480</td><td>Appendix NET, area of accumulation above the uterus</td></tr><tr><td>7</td><td>F</td><td>14</td><td>600</td><td>MEN-1, head of the pancreas NET and lymph n... |
9b0f5b9a698f7684fc212338979893c1f68f000267586ee6de1c380f83c8cb52.png | simple | <table><tr><td>Positive-to-Negative Ratio</td><td>Accuracy</td><td>F-Measure</td><td>MCC</td><td>Recall</td><td>Precision</td></tr><tr><td>1:1</td><td>0.6800</td><td>0.6667</td><td>0.3612</td><td>0.6400</td><td>0.6957</td></tr><tr><td>1:2</td><td>0.6667</td><td>0.5098</td><td>0.2638</td><td>0.5652</td><td>0.4643</td></... | <table><tr><td>Positive-to-Negative Ratio</td><td>Accuracy</td><td>F-Measure</td><td>MCC</td><td>Recall</td></tr><tr><td>1:1</td><td>0.6800</td><td>0.6667</td><td>0.3612</td><td>0.6400</td></tr><tr><td>1:2</td><td>0.6667</td><td>0.5098</td><td>0.2638</td><td>0.5652</td></tr><tr><td>1:3</td><td>0.6832</td><td>0.3043</td... | <table><tr><td>Precision</td></tr><tr><td>0.6957</td></tr><tr><td>0.4643</td></tr><tr><td>0.3043</td></tr></table> |
172fc78ca69c1bdd24e83c20f7f6f62b0dc6f50e40cc0e5d8e609213e9c01ea4.png | simple | <table><tr><td>Cell line</td><td>Media</td><td>Comment</td></tr><tr><td>1. 293</td><td>DMEM</td><td>Embryonic kidney</td></tr><tr><td>2. A549</td><td>DMEM</td><td>Adenocarcinomic alveolar basal epithelial</td></tr><tr><td>3. C33a</td><td>DMEM</td><td>Cervical carcinoma</td></tr><tr><td>4. DUT145</td><td>DMEM</td><td>Pr... | <table><tr><td>Cell line</td><td>Media</td></tr><tr><td>1. 293</td><td>DMEM</td></tr><tr><td>2. A549</td><td>DMEM</td></tr><tr><td>3. C33a</td><td>DMEM</td></tr><tr><td>4. DUT145</td><td>DMEM</td></tr><tr><td>5. H1229</td><td>RPMI</td></tr><tr><td>6. HaCAT</td><td>RPMI</td></tr><tr><td>7. HCT116</td><td>McCoy 5A</td></... | <table><tr><td>Comment</td></tr><tr><td>Embryonic kidney</td></tr><tr><td>Adenocarcinomic alveolar basal epithelial</td></tr><tr><td>Cervical carcinoma</td></tr><tr><td>Prostate cancer</td></tr><tr><td>Lung carcinoma</td></tr><tr><td>Immortalized, non-tumorigenic keratinocyte</td></tr><tr><td>Colorectal carcinoma</td><... |
5f69c08d5af0fc9393cfdcdf53309e3958b81a4aaffa689840e5c6314d9f8a2d.png | complex | <table><tr><td>Gene abbreviationa</td><td>Gene symbola</td><td>Accession no.b</td><td>Gene description</td><td>Gene group</td><td><i>Z</i>-Testc</td><td>Ratiod</td><td>95% CIe</td></tr><tr><td colspan="8">Up-regulated gene expression</td></tr><tr><td> <i>TECK</i>/<i>CCL25</i></td><td><i>Scya25</i></td><td>NM_009138</td... | <table><tr><td>Gene abbreviationa</td><td>Gene symbola</td><td>Accession no.b</td><td>Gene description</td><td>Gene group</td><td>Z-Testc</td><td>Ratiod</td><td>95% CIe</td></tr><tr><td colspan="8">Up-regulated gene expression</td></tr><tr><td>TECK/CCL25</td><td>Scya25</td><td>NM_009138</td><td>small inducible cytokine... | <table><tr><td>-5</td><td>Il5</td><td></td><td> 5</td><td>eukin</td><td> 10–4</td><td></td><td></td></tr><tr><td>VEGF-A</td><td>Vegf</td><td>NM_009505</td><td>vascular endothelial growth factor</td><td>Angiogenic factor</td><td>2.5 × 10–5</td><td>1.8</td><td>2.2–1.4</td></tr><tr><td colspan="8">Down-regulated gene expr... |
7f32dd2734a9883634d2d37379596910304d391dad00be26259e25b6208246c7.png | simple | <table><tr><td>Variables</td><td>Single-Pollutant Model</td><td>Model Adjusting PM<sub>2.5</sub></td><td><i>Z</i> Value *</td><td><i>p</i> Value *</td></tr><tr><td>NO<sub>2</sub></td><td></td><td></td><td></td><td></td></tr><tr><td>Lag0</td><td>0.40 (0.02 to 0.78)</td><td>0.72 (0.12 to 1.31)</td><td>−0.870</td><t... | <table><tr><td>Variables</td><td>Single-Pollutant Model</td><td>Model Adjusting PM2.5</td><td>Z Value *</td><td>p Value *</td></tr><tr><td>NO2</td><td></td><td></td><td></td><td></td></tr><tr><td>Lag0</td><td>0.40 (0.02 to 0.78)</td><td>0.72 (0.12 to 1.31)</td><td>−0.870</td><td>0.385</td></tr><tr><td>Lag1</td><td>−0.1... | <table><tr><td>Variables</td><td>Single-Pollutant Model</td><td>Model Adjusting PM2.5</td><td>Z Value *</td><td>p Value *</td></tr><tr><td>Lag0</td><td>−2.06 (−2.39 to −1.73)</td><td>−2.23 (−2.57 to −1.90)</td><td>0.732</td><td>0.464</td></tr><tr><td>Lag1</td><td>−1.48 (−1.78 to −1.18)</td><td>−1.54 (−1.85 to −1.22)</t... |
2246def6ec7866d01cf316d24279f3811aff45c08551dd799a5445e2c1735cc7.png | simple | <table><tr><td>Features<sup>$</sup></td><td>Starter Group</td><td>Experimental Group</td><td>P Value</td></tr><tr><td>P1 max</td><td>0.080 ± 0.080</td><td>0.044 ± 0.044</td><td>0.011 *</td></tr><tr><td>P1 mean</td><td>0.050 ± 0.049</td><td>0.030 ± 0.030</td><td>0.017 *</td></tr><tr><td>P2 max</td><t... | <table><tr><td>Features$</td><td>Starter Group</td><td>Experimental Group</td><td>P Value</td></tr><tr><td>P1 max</td><td>0.080 ± 0.080</td><td>0.044 ± 0.044</td><td>0.011 *</td></tr><tr><td>P1 mean</td><td>0.050 ± 0.049</td><td>0.030 ± 0.030</td><td>0.017 *</td></tr></table> | <table><tr><td>P2 max</td><td>0.114 ± 0.118</td><td>0.068 ± 0.072</td><td>0.024 *</td></tr><tr><td>P2 mean</td><td>0.082 ± 0.082</td><td>0.051 ± 0.055</td><td>0.029 *</td></tr><tr><td>P3 max</td><td>0.136 ± 0.129</td><td>0.070 ± 0.055</td><td>0.003 **</td></tr><tr><td>P3 mean</td><td>0.088 ± 0.083</td><td>0.058 ± 0.061... |
fd77e6861201c0d9c780940fec6f4ac9e2ff07a264e967da81f90c549476b2ec.png | simple | <table><tr><td>Organization</td><td>Country</td><td>Title</td><td>Year</td></tr><tr><td>National Institute of Health Care and Excellence</td><td>United Kingdom</td><td>Recognition, referral, diagnosis, and management of adults with autism</td><td>2012</td></tr><tr><td>Australian Psychological Association</td><td>Austra... | <table><tr><td>Organization</td><td>Country</td><td>Title</td><td>Year</td></tr><tr><td>National Institute of Health Care and Excellence</td><td>United Kingdom</td><td>Recognition, referral, diagnosis, and management of adults with autism</td><td>2012</td></tr><tr><td>Australian Psychological Association</td><td>Austra... | <table><tr><td>Organization</td><td>Country</td><td>Title</td><td>Year</td></tr><tr><td>Canadian Association of Occupational Therapists (CAOT)</td><td>Canada</td><td>Position Statement on Autism Spectrum Disorders and Occupational Therapy</td><td>2015</td></tr><tr><td>American Occupational Therapy Association (AOTA)</t... |
e5009c0a5da12599a5feedbc349aea0b6fe3bb2f96ca7f71fd69743103da1537.png | complex | <table><tr><td>Coefficients of variation (CVs)</td><td colspan="2">Children groups</td><td colspan="3">ANOVA</td></tr><tr><td></td><td>Spastic CP (n =10)</td><td>TD (n =10)</td><td><i>F</i><sub><i>1,18</i></sub></td><td><i>p </i>value</td><td>Effect size <i>d</i></td></tr><tr><td>Utterance duration</td><td></td><td></t... | <table><tr><td>Coefficients of variation (CVs)</td><td colspan="2">Children groups</td><td colspan="3">ANOVA</td></tr></table> | <table><tr><td></td><td>Spastic CP (n =10)</td><td>TD (n =10)</td><td>F1,18</td><td>p value</td><td>Effect size d</td></tr><tr><td>Utterance duration</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mono-syllable task</td><td>17.87 ± 11.87</td><td>5.23 ± 2.33</td><td>10.923</td><td>0.004*</td><td>0.615</td... |
bff30c1665095de1bdef7485a9a892f54793aa272d8fc307c66f7bd7a76b228c.png | simple | <table><tr><td></td><td>Blastn (WGS <i>An. gambiae</i>)</td><td>Blastx (Nr)</td><td>Blastn (Nr)</td><td>Blastn (dbEST)</td><td>Unannotated</td><td>Total</td></tr><tr><td>3 Positive Controls</td><td>No Significant Hit</td><td>3</td><td></td><td></td><td></td><td>3</td></tr><tr><td>403 Unique Transcripts</td><td>403</td>... | <table><tr><td></td><td>Blastn (WGS An. gambiae)</td></tr><tr><td>3 Positive Controls</td><td>No Significant Hit</td></tr><tr><td>403 Unique Transcripts</td><td>403</td></tr><tr><td>Early Genes</td><td>144</td></tr><tr><td>Middle Genes</td><td>130</td></tr><tr><td>Late Genes</td><td>139</td></tr><tr><td>Total</td><td>4... | <table><tr><td>Blastx (Nr)</td><td>Blastn (Nr)</td><td>Blastn (dbEST)</td><td>Unannotated</td><td>Total</td></tr><tr><td>3</td><td></td><td></td><td></td><td>3</td></tr><tr><td>240</td><td>8</td><td>112</td><td>43</td><td>403</td></tr><tr><td>77</td><td>2</td><td>45</td><td>20</td><td>144</td></tr><tr><td>78</td><td>6<... |
945ee74b6ea15b51df9bcfd1958807dd088bc654551fbebb156cf02086f2215b.png | simple | <table><tr><td>Study</td><td>Bacterial strain</td><td>Preparation</td><td>Patient population</td><td>Intervention</td><td>Results</td></tr><tr><td> </td><td> </td><td> </td><td>Cell or animal type</td><td> </td><td> </td></tr><tr><td><i>In vitro</i> experiments</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr... | <table><tr><td>Study</td><td>Bacterial strain</td><td>Preparation</td><td>Patient population</td><td>Intervention</td><td>Results</td></tr><tr><td></td><td></td><td></td><td>Cell or animal type</td><td></td><td></td></tr><tr><td>In vitro experiments</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Strunk e... | <table><tr><td>Ivarsson et al.,104 2013</td><td>Clinical isolate</td><td>Live bacteria</td><td>Vascular endothelial cells</td><td>18 h</td><td>IL-8, ICAM-1 ↑</td></tr><tr><td></td><td></td><td>104cfu/ml</td><td>Small airway epithelial cells</td><td></td><td>Pro-inflammatory effect: SE > SA</td></tr><tr><td>Hussain et a... |
f7493e4a79f93769ff7ce7b2a11591396534704fa6fb47b4fad14968c912ea42.png | complex | <table><tr><td>Characteristic</td><td>S‐HFpEF (n=83)</td><td>AD‐HFpEF (n=78)</td><td>Overall (n=161)</td><td><i>P</i> Value</td></tr><tr><td colspan="5">Demographics</td></tr><tr><td>Age, years: n, median (25th–75th)</td><td>83, 72 (65–79)</td><td>78, 73 (65–79)</td><td>161, 72 (65–7... | <table><tr><td>Characteristic</td><td>S‐HFpEF (n=83)</td><td>AD‐HFpEF (n=78)</td><td>Overall (n=161)</td><td>P Value</td></tr><tr><td colspan="5">Demographics</td></tr><tr><td>Age, years: n, median (25th–75th)</td><td>83, 72 (65–79)</td><td>78, 73 (65–79)</td><td>161, 72 (65–79)</td><td>0.970</td></tr><tr><td>Male sex<... | <table><tr><td>Characteristic</td><td>S‐HFpEF (n=83)</td><td>AD‐HFpEF (n=78)</td><td>Overall (n=161)</td><td>P Value</td></tr><tr><td>Heart rate, beats/min: n, median (25th–75th)</td><td>83, 69 (62–80)</td><td>78, 72 (65–84)</td><td>161, 72 (62–80)</td><td>0.073</td></tr><tr><td>JVP≥8 cm</td><td>36/80 (45.0%)</td><td>6... |
d7fd17285b9b614e1273d81bd476bac81094693a940bf49a6303f6032542f944.png | simple | <table><tr><td></td><td>2005</td><td>2006</td><td>2007</td><td>2008</td><td>2009</td><td>2010</td><td>TOTAL</td></tr><tr><td>Horses</td><td>783</td><td>822</td><td>1,506</td><td>2,002</td><td>3,220</td><td>7,296</td><td>15,629</td></tr></table> | <table><tr><td></td><td>2005</td><td>2006</td><td>2007</td><td>2008</td><td>2009</td><td>2010</td><td>TOTAL</td></tr></table> | <table><tr><td>Horses</td><td>783</td><td>822</td><td>1,506</td><td>2,002</td><td>3,220</td><td>7,296</td><td>15,629</td></tr></table> |
9d394a4d5043d39968ae3478c3affe2424a3dedbb710f0d6ff07feb7132dbeb0.png | complex | <table><tr><td>LNR group</td><td>Ratio/Node quota</td><td>N</td><td>Differentiation grade (well/med./poor)</td><td>N-status (N1/N2)</td><td colspan="2">Lymph nodes (median)</td><td>Chemotherapy eligibility (yes/no)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Assessed</td><td>Positive</td><td></td></tr... | <table><tr><td>LNR group</td><td>Ratio/Node quota</td><td>N</td><td>Differentiation grade (well/med./poor)</td><td>N-status (N1/N2)</td><td>Lymph nodes (median)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Assessed</td></tr><tr><td>1</td><td>0–0.15</td><td>46</td><td>4/36/6</td><td>46/0</td><td>10 (1–1... | <table><tr><td>Lymph nodes (median)</td><td>Chemotherapy eligibility (yes/no)</td></tr><tr><td>Positive</td><td></td></tr><tr><td>1 (0–3)</td><td>27/19</td></tr><tr><td>4 (1–11)</td><td>23/22</td></tr><tr><td>8 (2–26)</td><td>27/18</td></tr><tr><td>4 (0–26)</td><td>77/59</td></tr></table> |
c5ea052a29d88258211cd8c57694e5d7cc643c2220b3a4d067224df55cb80e37.png | complex | <table><tr><td>Drug’s name</td><td>Dose</td><td>Comments</td></tr><tr><td>Vasodilator drugs (hypotensives)</td><td></td><td></td></tr><tr><td>Propofol</td><td>2 - 2.5 mg/kg load, 25 - 75 μg/kg/min maintain</td><td>Local irritation, propofol infusion syndrome</td></tr><tr><td>Remifentanil</td><td>1 μg/kg... | <table><tr><td>Drug’s name</td></tr><tr><td>Vasodilator drugs (hypotensives)</td></tr><tr><td>Propofol</td></tr><tr><td>Remifentanil</td></tr><tr><td>Dexmetedomidine</td></tr><tr><td>Nitroprusside</td></tr><tr><td>Nitroglycerine</td></tr><tr><td>Nicardipine</td></tr><tr><td>Esmolol</td></tr><tr><td>Labetalol</td></tr><... | <table><tr><td>Dose</td><td>Comments</td></tr><tr><td></td><td></td></tr><tr><td>2 - 2.5 mg/kg load, 25 - 75 μg/kg/min maintain</td><td>Local irritation, propofol infusion syndrome</td></tr><tr><td>1 μg/kg load, 0.05 μg/kg/min maintain</td><td>Respiratory depression, hyperalgesia, vomiting</td></tr><tr><td>1 mg/kg load... |
3ac73b3b3175342232519dd0da70c25131e6fe5cd62be66156b13d79e0fb86b1.png | simple | <table><tr><td>Mean (SD)</td><td>Non-atopic asthma n = 37</td><td>Atopic asthma n = 137</td><td><i>p value</i></td></tr><tr><td>HAD-Anxiety</td><td>8.43 (4.35)</td><td>7.98 (4.45)</td><td><i>0.607</i></td></tr><tr><td>HAD-Depression</td><td>7.57 (4.52)</td><td>6.85 (4.43)</td><td><i>0.277</i></td></tr><tr><td>HAD- Tota... | <table><tr><td>Mean (SD)</td><td>Non-atopic asthma n = 37</td><td>Atopic asthma n = 137</td><td>p value</td></tr></table> | <table><tr><td>HAD-Anxiety</td><td>8.43 (4.35)</td><td>7.98 (4.45)</td><td>0.607</td></tr><tr><td>HAD-Depression</td><td>7.57 (4.52)</td><td>6.85 (4.43)</td><td>0.277</td></tr><tr><td>HAD- Total</td><td>16.00 (7.51)</td><td>14.82 (8.10)</td><td>0.302</td></tr><tr><td>ACT</td><td>17.97 (4.89)</td><td>18.42 (5.18)</td><t... |
609d713dc3f57dd89d2fd4f943bd3dfacc4d9d14b7f050ead288de7347e0f93a.png | simple | <table><tr><td>Intervention</td><td>At Risk Target Population</td><td>Numbers at Risk Reached</td><td>% of Identified at Risk Reached by the RED Strategy</td><td>General Target Population in RED Catchment Areas</td><td>% of Additional Population Reached through the RED Strategy</td></tr><tr><td>Additional immunized chi... | <table><tr><td>Intervention</td><td>At Risk Target Population</td><td>Numbers at Risk Reached</td><td>% of Identified at Risk Reached by the RED Strategy</td><td>General Target Population in RED Catchment Areas</td><td>% of Additional Population Reached through the RED Strategy</td></tr><tr><td>Additional immunized chi... | <table><tr><td>Additional ANC care contacts</td><td>515</td><td>508</td><td>98.64</td><td>5616(Total ANC Contacts in RED Area)</td><td>9% of all ANC Contacts</td></tr><tr><td>Additional family planning contacts</td><td>1047</td><td>1047</td><td>100.00</td><td>96560(Total Family Planning Contacts in RED Area)</td><td>1.... |
dd09189e36cd7c766a96b7d4c21c7c891dcd7335c7e11a935838b8a192c26a0e.png | complex | <table><tr><td></td><td>Total</td><td>Previously incarcerated N(%)</td><td>First incarceration N(%)</td><td>Crude odds ratio (95% CI)</td><td>Adjusted odds ratio (95% CI), <i>P</i></td></tr><tr><td><i>Age</i> in years Mean [SD]</td><td>707</td><td>32 [10.5]</td><td>28.1 [10.3]</td><td>1 (0.99–1.02)</td><td>1.04(1... | <table><tr><td></td><td>Total</td><td>Previously incarcerated N(%)</td><td>First incarceration N(%)</td><td>Crude odds ratio (95% CI)</td><td>Adjusted odds ratio (95% CI), P</td></tr><tr><td>Age in years Mean [SD]</td><td>707</td><td>32 [10.5]</td><td>28.1 [10.3]</td><td>1 (0.99–1.02)</td><td>1.04(1.02–1.06), P < 0.001... | <table><tr><td>o</td><td>48659</td><td>7.9)317(92.1)</td><td></td><td>.4 (0.7–2.5)</td><td>0.5</td></tr><tr><td colspan="6">Manic</td></tr><tr><td>Yes No</td><td>26681</td><td>18(5.2)326(94.8)</td><td>8(2.2)355(97.8)</td><td>2.56 (1.05–5.7)</td><td>1.3 (0.5–3.6), P = 0.5</td></tr><tr><td colspan="6">Mood disorders</td>... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.